Epstein-barr	O
virus	O
immediate-early	B-protein
protein	I-protein
BZLF1	I-protein
is	O
SUMO-1	O
modified	O
and	O
disrupts	O
promyelocytic	O
leukemia	O
bodies	O
.	O

Although	O
the	O
immediate-early	B-protein
proteins	I-protein
of	O
both	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
known	O
to	O
modify	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
(	O
ND10	O
)	O
bodies	O
in	O
the	O
nucleus	O
of	O
the	O
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	O
with	O
gamma	O
herpesviruses	O
induces	O
a	O
similar	O
effect	O
.	O

The	O
PML	B-protein
protein	I-protein
is	O
induced	O
by	O
interferon	B-protein
,	O
involved	O
in	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
presentation	O
,	O
and	O
necessary	O
for	O
certain	O
types	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
PML	O
bodies	O
function	O
in	O
an	O
antiviral	O
capacity	O
.	O

SUMO-1	O
modification	O
of	O
PML	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
the	O
formation	O
of	O
PML	O
bodies	O
.	O

To	O
examine	O
whether	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
replication	O
interferes	O
with	O
PML	O
bodies	O
,	O
we	O
expressed	O
the	O
EBV	B-DNA
immediate-early	I-DNA
genes	I-DNA
BZLF1	B-DNA
(	I-DNA
Z	I-DNA
)	I-DNA
and	O
BRLF1	B-DNA
(	I-DNA
R	I-DNA
)	I-DNA
in	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
examined	O
PML	B-protein
localization	O
.	O

Both	O
Z	O
and	O
R	O
expression	O
resulted	O
in	O
PML	B-protein
dispersion	O
in	O
EBV-positive	B-cell_type
cells	I-cell_type
.	O

Z	O
but	O
not	O
R	O
expression	O
is	O
sufficient	O
to	O
disrupt	O
PML	O
bodies	O
in	O
EBV-negative	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
show	O
that	O
dispersion	O
of	O
PML	O
bodies	O
by	O
Z	B-DNA
requires	O
a	O
portion	O
of	O
the	O
transcriptional	B-DNA
activation	I-DNA
domain	I-DNA
of	O
Z	B-DNA
but	O
not	O
the	O
DNA-binding	O
function	O
.	O

As	O
was	O
previously	O
reported	O
for	O
the	O
HSV-1	B-protein
ICP0	I-protein
and	I-protein
CMV	I-protein
IE1	I-protein
proteins	I-protein
,	O
Z	B-DNA
reduces	O
the	O
amount	O
of	O
SUMO-1-modified	B-protein
PML	I-protein
.	O

We	O
also	O
found	O
that	O
Z	B-DNA
itself	O
is	O
SUMO-1	O
modified	O
(	O
through	O
amino	O
acid	O
12	O
)	O
and	O
that	O
Z	B-DNA
competes	O
with	O
PML	B-protein
for	O
limiting	O
amounts	O
of	O
SUMO-1	B-protein
.	O

These	O
results	O
suggest	O
that	O
disruption	O
of	O
PML	O
bodies	O
is	O
important	O
for	O
efficient	O
lytic	O
replication	O
of	O
EBV	O
.	O

Furthermore	O
,	O
Z	B-DNA
may	O
potentially	O
alter	O
the	O
function	O
of	O
a	O
variety	O
of	O
cellular	O
proteins	O
by	O
inhibiting	O
SUMO-1	O
modification	O

JOURNAL	NULL
or	NULL
VirRoLOGY	NULL
,	NULL
Mar	NULL
.	NULL

2001	NULL
,	NULL
p.	NULL
2388-2399	NULL
0022-538X/01/	NULL
$	NULL
04.00+0	NULL
_	NULL
DOI	NULL
:	NULL
10.1128/JV1.75.5.2388-2399.2001	NULL
Vol	NULL
.	NULL

75	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Copyright	NULL
Â©	NULL
2001	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Epstein-Barr	NULL
Virus	NULL
Immediate-Early	NULL
Protein	NULL
BZLF1	NULL
Is	NULL
SUMO-1	NULL
Modified	NULL
and	NULL
Disrupts	NULL
Promyelocytic	NULL
Leukemia	NULL
Bodies	NULL
AMY	NULL
L.	NULL
ADAMSON	NULL
'	NULL
f	NULL
anp	NULL
SHANNON	NULL
KENNEY**	NULL
Lineberger	NULL
Comprehensive	NULL
Cancer	NULL
Center	NULL
'	NULL
and	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Microbiology	NULL
,	NULL
``	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Chapel	NULL
Hill	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
North	NULL
Carolina	NULL
27599-7295	NULL
Received	NULL
3	NULL
July	NULL
2000/Accepted	NULL
17	NULL
November	NULL
2000	NULL
Although	NULL
the	NULL
immediate-early	NULL
proteins	NULL
of	NULL
both	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
and	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
are	NULL
known	NULL
to	NULL
modify	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
)	NULL
(	NULL
ND10	NULL
)	NULL
bodies	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
the	NULL
host	NULL
cell	NULL
,	NULL
it	NULL
has	NULL
been	NULL
unclear	NULL
whether	NULL
lytic	NULL
infection	NULL
with	NULL
gamma	NULL
herpesviruses	NULL
induces	NULL
a	NULL
similar	NULL
effect	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
is	NULL
induced	NULL
by	NULL
interferon	NULL
,	NULL
involved	NULL
in	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
presentation	NULL
,	NULL
and	NULL
necessary	NULL
for	NULL
certain	NULL
types	NULL
of	NULL
apoptosis	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
PML	NULL
bodies	NULL
function	NULL
in	NULL
an	NULL
antiviral	NULL
capacity	NULL
.	NULL

SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
is	NULL
known	NULL
to	NULL
be	NULL
required	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
PML	NULL
bodies	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
lytic	NULL
replication	NULL
interferes	NULL
with	NULL
PML	NULL
bodies	NULL
,	NULL
we	NULL
expressed	NULL
the	NULL
EBV	NULL
immediate-early	NULL
genes	NULL
BZLF1L	NULL
(	NULL
Z	NULL
)	NULL
and	NULL
BRLF1	NULL
(	NULL
R	NULL
)	NULL
in	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
and	NULL
examined	NULL
PML	NULL
localization	NULL
.	NULL

Both	NULL
Z	NULL
and	NULL
R	NULL
expression	NULL
resulted	NULL
in	NULL
PML	NULL
dispersion	NULL
in	NULL
EBV-positive	NULL
cells	NULL
.	NULL

Z	NULL
but	NULL
not	NULL
R	NULL
expression	NULL
is	NULL
sufficient	NULL
to	NULL
disrupt	NULL
PML	NULL
bodies	NULL
in	NULL
EBV-negative	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
show	NULL
that	NULL
dispersion	NULL
of	NULL
PML	NULL
bodies	NULL
by	NULL
Z	NULL
requires	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
transcriptional	NULL
activation	NULL
domain	NULL
of	NULL
Z	NULL
but	NULL
not	NULL
the	NULL
DNA-binding	NULL
function	NULL
.	NULL

As	NULL
was	NULL
previously	NULL
reported	NULL
for	NULL
the	NULL
HSV-1	NULL
ICPO	NULL
and	NULL
CMV	NULL
IE1	NULL
proteins	NULL
,	NULL
Z	NULL
reduces	NULL
the	NULL
amount	NULL
of	NULL
SUMO-1-modified	NULL
PML	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
Z	NULL
itself	NULL
is	NULL
SUMO-1	NULL
modified	NULL
(	NULL
through	NULL
amino	NULL
acid	NULL
12	NULL
)	NULL
and	NULL
that	NULL
Z	NULL
competes	NULL
with	NULL
PML	NULL
for	NULL
limiting	NULL
amounts	NULL
of	NULL
SUMO-1	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
disruption	NULL
of	NULL
PML	NULL
bodies	NULL
is	NULL
important	NULL
for	NULL
efficient	NULL
lytic	NULL
replication	NULL
of	NULL
EBV	NULL
.	NULL

Furthermore	NULL
,	NULL
Z	NULL
may	NULL
potentially	NULL
alter	NULL
the	NULL
function	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
proteins	NULL
by	NULL
inhibiting	NULL
SUMO-1	NULL
modification	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
human	NULL
herpesvirus	NULL
family	NULL
of	NULL
viruses	NULL
and	NULL
infects	NULL
approximately	NULL
90	NULL
%	NULL
of	NULL
the	NULL
world	NULL
's	NULL
population	NULL
.	NULL

EBV	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
clinical	NULL
syndrome	NULL
infectious	NULL
mononucleosis	NULL
(	NULL
66	NULL
)	NULL
and	NULL
is	NULL
found	NULL
in	NULL
various	NULL
tumors	NULL
,	NULL
including	NULL
nasopharyngeal	NULL
carcinoma	NULL
and	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
(	NULL
66	NULL
,	NULL
88	NULL
)	NULL
.	NULL

Upon	NULL
infection	NULL
of	NULL
the	NULL
host	NULL
,	NULL
EBV	NULL
initially	NULL
replicates	NULL
within	NULL
epithelial	NULL
cells	NULL
in	NULL
the	NULL
oropharynx	NULL
(	NULL
44	NULL
,	NULL
52	NULL
,	NULL
66	NULL
,	NULL
71	NULL
)	NULL
and	NULL
subsequently	NULL
infects	NULL
B	NULL
cells	NULL
trafficking	NULL
through	NULL
the	NULL
pharynx	NULL
.	NULL

In	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
virus	NULL
usually	NULL
converts	NULL
to	NULL
a	NULL
latent	NULL
form	NULL
and	NULL
persists	NULL
indefinitely	NULL
in	NULL
the	NULL
host	NULL
(	NULL
44	NULL
,	NULL
52	NULL
,	NULL
66	NULL
,	NULL
71	NULL
)	NULL
.	NULL

During	NULL
latency	NULL
,	NULL
only	NULL
a	NULL
small	NULL
subset	NULL
of	NULL
EBV-encoded	NULL
proteins	NULL
are	NULL
ex-pressed	NULL
.	NULL

Occasionally	NULL
,	NULL
the	NULL
latent	NULL
virus	NULL
within	NULL
B	NULL
cells	NULL
switches	NULL
back	NULL
to	NULL
the	NULL
lytic	NULL
mode	NULL
of	NULL
replication	NULL
(	NULL
66	NULL
)	NULL
.	NULL

Virus	NULL
released	NULL
from	NULL
B	NULL
cells	NULL
then	NULL
reinfects	NULL
pharyngeal	NULL
epithelial	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
secretion	NULL
of	NULL
infectious	NULL
virus	NULL
into	NULL
the	NULL
saliva	NULL
.	NULL

The	NULL
first	NULL
EBV	NULL
genes	NULL
expressed	NULL
during	NULL
the	NULL
lytic	NULL
form	NULL
of	NULL
viral	NULL
replication	NULL
are	NULL
the	NULL
immediate-early	NULL
genes	NULL
BZLF1	NULL
(	NULL
Z	NULL
)	NULL
and	NULL
BRLF1	NULL
(	NULL
R	NULL
)	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
Z	NULL
and	NULL
R	NULL
proteins	NULL
function	NULL
as	NULL
transcriptional	NULL
activators	NULL
and	NULL
induce	NULL
expression	NULL
of	NULL
the	NULL
next	NULL
tier	NULL
of	NULL
EBV	NULL
genes	NULL
,	NULL
the	NULL
early	NULL
genes	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
28	NULL
,	NULL
32	NULL
,	NULL
33	NULL
,	NULL
36	NULL
,	NULL
41	NULL
,	NULL
53	NULL
,	NULL
64	NULL
,	NULL
67	NULL
,	NULL
68	NULL
,	NULL
75	NULL
,	NULL
78	NULL
)	NULL
.	NULL

The	NULL
early	NULL
genes	NULL
encode	NULL
the	NULL
viral	NULL
proteins	NULL
required	NULL
for	NULL
EBV	NULL
DNA	NULL
replication	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Viral	NULL
DNA	NULL
replication	NULL
is	NULL
followed	NULL
by	NULL
EBV	NULL
late-gene	NULL
expression	NULL
and	NULL
packaging	NULL
of	NULL
the	NULL
virus	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Viruses	NULL
often	NULL
manipulate	NULL
their	NULL
host	NULL
's	NULL
cellular	NULL
environment	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Lineberger	NULL
Comprehensive	NULL
Cancer	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Chapel	NULL
Hill	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
27599-7295	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
919	NULL
)	NULL
966-1248	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
919	NULL
)	NULL
966-8212	NULL
.	NULL

E-mail	NULL
:	NULL
shann	NULL
@	NULL
med.unc.edu	NULL
.	NULL

i	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Greensboro	NULL
,	NULL
Greensboro	NULL
,	NULL
NC	NULL
27402	NULL
.	NULL

2388	NULL
in	NULL
order	NULL
to	NULL
create	NULL
favorable	NULL
conditions	NULL
for	NULL
viral	NULL
replication	NULL
and	NULL
survival	NULL
.	NULL

Virally	NULL
induced	NULL
changes	NULL
include	NULL
modulation	NULL
of	NULL
host	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
signal	NULL
transduction	NULL
cascades	NULL
,	NULL
and	NULL
transcriptional	NULL
functions	NULL
,	NULL
among	NULL
others	NULL
.	NULL

Notably	NULL
,	NULL
a	NULL
number	NULL
of	NULL
vi-ruses	NULL
,	NULL
including	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HSV-1	NULL
)	NULL
and	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
,	NULL
disperse	NULL
nuclear	NULL
structures	NULL
known	NULL
as	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
,	NULL
also	NULL
called	NULL
nuclear	NULL
domain	NULL
10	NULL
[	NULL
ND10	NULL
]	NULL
)	NULL
bodies	NULL
.	NULL

The	NULL
viral	NULL
proteins	NULL
responsible	NULL
for	NULL
PML	NULL
body	NULL
dispersion	NULL
in	NULL
HSV-1	NULL
and	NULL
CMV	NULL
are	NULL
the	NULL
immediate-early	NULL
proteins	NULL
HSV-1	NULL
ICPO	NULL
and	NULL
CMV	NULL
IE1	NULL
(	NULL
3	NULL
,	NULL
4	NULL
,	NULL
23	NULL
,	NULL
40	NULL
,	NULL
46	NULL
,	NULL
57	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
ICPO	NULL
mutants	NULL
(	NULL
containing	NULL
alterations	NULL
within	NULL
the	NULL
RING	NULL
finger	NULL
)	NULL
which	NULL
can	NULL
not	NULL
disperse	NULL
PML	NULL
bodies	NULL
also	NULL
fail	NULL
to	NULL
activate	NULL
gene	NULL
expression	NULL
and	NULL
can	NULL
not	NULL
replicate	NULL
efficiently	NULL
,	NULL
suggesting	NULL
a	NULL
link	NULL
between	NULL
PML	NULL
bodies	NULL
and	NULL
viral	NULL
replication	NULL
(	NULL
21	NULL
)	NULL
.	NULL

PML-containing	NULL
nuclear	NULL
bodies	NULL
are	NULL
made	NULL
up	NULL
of	NULL
several	NULL
proteins	NULL
,	NULL
including	NULL
CREB-binding	NULL
protein	NULL
(	NULL
CBP	NULL
)	NULL
,	NULL
Sp100	NULL
,	NULL
Rb	NULL
,	NULL
Daxx	NULL
,	NULL
ISG20	NULL
,	NULL
and	NULL
the	NULL
small	NULL
ubiquitin-related	NULL
modifier	NULL
SUMO-1	NULL
(	NULL
6	NULL
,	NULL
31	NULL
,	NULL
48	NULL
,	NULL
74	NULL
,	NULL
87	NULL
)	NULL
.	NULL

However	NULL
,	NULL
only	NULL
the	NULL
PML	NULL
protein	NULL
is	NULL
known	NULL
to	NULL
be	NULL
absolutely	NULL
essential	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
these	NULL
bodies	NULL
(	NULL
86	NULL
)	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
was	NULL
initially	NULL
identified	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
PML	NULL
who	NULL
harbored	NULL
a	NULL
translocation	NULL
resulting	NULL
in	NULL
a	NULL
fusion	NULL
protein	NULL
between	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
Â«	NULL
and	NULL
PML	NULL
protein	NULL
(	NULL
18	NULL
,	NULL
30	NULL
,	NULL
34	NULL
,	NULL
38	NULL
,	NULL
58	NULL
,	NULL
62	NULL
)	NULL
.	NULL

This	NULL
RARa-PML	NULL
fusion	NULL
protein	NULL
prevents	NULL
PML	NULL
protein	NULL
from	NULL
localizing	NULL
in	NULL
nuclear	NULL
bodies	NULL
(	NULL
20	NULL
,	NULL
45	NULL
,	NULL
80	NULL
)	NULL
,	NULL
which	NULL
normally	NULL
appear	NULL
as	NULL
10	NULL
to	NULL
30	NULL
discrete	NULL
dots	NULL
(	NULL
depending	NULL
upon	NULL
cell	NULL
type	NULL
)	NULL
within	NULL
the	NULL
nucleus	NULL
.	NULL

Treatment	NULL
with	NULL
retinoic	NULL
acid	NULL
leads	NULL
to	NULL
degradation	NULL
of	NULL
the	NULL
RARa	NULL
Â«	NULL
-PML	NULL
fusion	NULL
protein	NULL
,	NULL
proper	NULL
PML	NULL
protein	NULL
localization	NULL
,	NULL
and	NULL
cancer	NULL
remission	NULL
(	NULL
34	NULL
,	NULL
58	NULL
)	NULL
.	NULL

The	NULL
wild-type	NULL
PML	NULL
protein	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
presentation	NULL
(	NULL
85	NULL
)	NULL
and	NULL
is	NULL
required	NULL
for	NULL
certain	NULL
types	NULL
of	NULL
apoptosis	NULL
(	NULL
10	NULL
,	NULL
24	NULL
,	NULL
37	NULL
,	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
51	NULL
,	NULL
63	NULL
,	NULL
77	NULL
,	NULL
79	NULL
,	NULL
87	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PML	NULL
protein	NULL
expression	NULL
is	NULL
induced	NULL
by	NULL
type	NULL
I	NULL
and	NULL
II	NULL
interferons	NULL
(	NULL
27	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
PML	NULL
protein	NULL
functions	NULL
in	NULL
an	NULL
antiviral	NULL
as	NULL
well	NULL
as	NULL
antitumor	NULL
capacity	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
be	NULL
covalently	NULL
modified	NULL
by	NULL
the	NULL
SUMO-1	NULL
protein	NULL
(	NULL
8	NULL
,	NULL
60	NULL
,	NULL
72	NULL
)	NULL
.	NULL

SUMO-1	NULL
is	NULL
an	NULL
11.5-kDa	NULL
protein	NULL
that	NULL
is	NULL
homologous	NULL
to	NULL
ubiquitin	NULL
(	NULL
8	NULL
,	NULL
39	NULL
,	NULL
49	NULL
,	NULL
54	NULL
,	NULL
56	NULL
,	NULL
70	NULL
)	NULL
;	NULL
however	NULL
,	NULL
SUMO-1	NULL
does	NULL
not	NULL
function	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
as	NULL
ubiquitin	NULL
.	NULL

SUMO-1	NULL
becomes	NULL
covalently	NULL
attached	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
proteins	NULL
,	NULL
including	NULL
PML	NULL
,	NULL
RanGAP1	NULL
,	NULL
and	NULL
IxB	NULL
,	NULL
and	NULL
serves	NULL
to	NULL
localize	NULL
and/or	NULL
stabilize	NULL
these	NULL
proteins	NULL
(	NULL
8	NULL
,	NULL
17	NULL
,	NULL
55	NULL
,	NULL
60	NULL
,	NULL
72	NULL
)	NULL
.	NULL

The	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
is	NULL
required	NULL
for	NULL
its	NULL
localization	NULL
to	NULL
nuclear	NULL
bodies	NULL
(	NULL
60	NULL
,	NULL
86	NULL
)	NULL
.	NULL

SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
is	NULL
also	NULL
required	NULL
for	NULL
the	NULL
localization	NULL
of	NULL
several	NULL
other	NULL
proteins	NULL
,	NULL
including	NULL
Sp100	NULL
,	NULL
Daxx	NULL
,	NULL
CBP	NULL
,	NULL
and	NULL
ISG20	NULL
,	NULL
into	NULL
PML	NULL
bodies	NULL
(	NULL
86	NULL
)	NULL
.	NULL

HSV-1	NULL
and	NULL
CMV	NULL
were	NULL
both	NULL
recently	NULL
shown	NULL
to	NULL
disrupt	NULL
PML	NULL
bodies	NULL
by	NULL
inhibiting	NULL
the	NULL
formation	NULL
of	NULL
SUMO-1-modified	NULL
species	NULL
of	NULL
PML	NULL
protein	NULL
(	NULL
13	NULL
,	NULL
22	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
CMV	NULL
immediate-early	NULL
protein	NULL
IE1	NULL
(	NULL
as	NULL
well	NULL
as	NULL
the	NULL
IE2	NULL
protein	NULL
)	NULL
is	NULL
itself	NULL
SUMO-1	NULL
modified	NULL
(	NULL
35	NULL
,	NULL
59	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
both	NULL
alphaherpes-viruses	NULL
(	NULL
HSV	NULL
)	NULL
and	NULL
betaherpesviruses	NULL
(	NULL
CMV	NULL
)	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
in	NULL
the	NULL
host	NULL
cell	NULL
suggests	NULL
that	NULL
this	NULL
function	NULL
may	NULL
be	NULL
universally	NULL
important	NULL
for	NULL
efficient	NULL
herpesvirus	NULL
replication	NULL
,	NULL
including	NULL
gammaherpesviruses	NULL
such	NULL
as	NULL
EBV	NULL
.	NULL

However	NULL
,	NULL
to	NULL
our	NULL
knowledge	NULL
the	NULL
effect	NULL
of	NULL
lytic	NULL
EBV	NULL
infection	NULL
on	NULL
PML	NULL
bodies	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
examined	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
difficulty	NULL
of	NULL
inducing	NULL
efficient	NULL
lytic	NULL
EBV	NULL
infection	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
lytic	NULL
EBV	NULL
infection	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
.	NULL

We	NULL
show	NULL
that	NULL
induction	NULL
of	NULL
the	NULL
lytic	NULL
form	NULL
of	NULL
EBV	NULL
infection	NULL
using	NULL
either	NULL
expression	NULL
vectors	NULL
for	NULL
Z	NULL
or	NULL
R	NULL
or	NULL
an	NULL
adenovirus	NULL
vector	NULL
that	NULL
expresses	NULL
Z	NULL
leads	NULL
to	NULL
dispersion	NULL
of	NULL
PML	NULL
bodies	NULL
in	NULL
EBV-positive	NULL
cells	NULL
.	NULL

In	NULL
EBV-negative	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
immediate-early	NULL
protein	NULL
Z	NULL
alone	NULL
but	NULL
not	NULL
R	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
.	NULL

The	NULL
dispersal	NULL
of	NULL
PML	NULL
bodies	NULL
is	NULL
coincident	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
high-molecular-weight	NULL
(	NULL
SUMO-1-modified	NULL
)	NULL
isoforms	NULL
of	NULL
PML	NULL
bodies	NULL
.	NULL

In	NULL
transfection	NULL
assays	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
first	NULL
86	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
(	NULL
which	NULL
encode	NULL
the	NULL
transcriptional	NULL
activation	NULL
domain	NULL
as	NULL
well	NULL
as	NULL
a	NULL
replication	NULL
function	NULL
)	NULL
are	NULL
required	NULL
for	NULL
PML	NULL
body	NULL
dispersion	NULL
.	NULL

We	NULL
have	NULL
also	NULL
discovered	NULL
that	NULL
Z	NULL
itself	NULL
is	NULL
SUMO-1	NULL
modified	NULL
at	NULL
amino	NULL
acid	NULL
12	NULL
.	NULL

Additionally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
Z	NULL
is	NULL
able	NULL
to	NULL
outcompete	NULL
PML	NULL
bodies	NULL
for	NULL
SUMO-1	NULL
modification	NULL
and	NULL
that	NULL
competition	NULL
for	NULL
SUMO-1	NULL
modification	NULL
requires	NULL
the	NULL
lysine	NULL
at	NULL
amino	NULL
acid	NULL
12	NULL
.	NULL

The	NULL
disruption	NULL
of	NULL
PML	NULL
bodies	NULL
by	NULL
all	NULL
classes	NULL
of	NULL
herpesviruses	NULL
suggests	NULL
that	NULL
this	NULL
function	NULL
is	NULL
important	NULL
for	NULL
efficient	NULL
lytic	NULL
replication	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

DG75	NULL
is	NULL
an	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
Akata	NULL
is	NULL
an	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
.	NULL

B-cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

A549	NULL
is	NULL
a	NULL
human	NULL
lung	NULL
carcinoma	NULL
line	NULL
.	NULL

HeLa	NULL
is	NULL
a	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
.	NULL

D98/HE-R-1	NULL
is	NULL
an	NULL
EBV-positive	NULL
epithelial	NULL
cell	NULL
line	NULL
formed	NULL
by	NULL
the	NULL
fusion	NULL
of	NULL
an	NULL
HeLa	NULL
subclone	NULL
(	NULL
D98	NULL
)	NULL
with	NULL
the	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
P3HR/1	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Epithelial	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
H	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Akata	NULL
cell	NULL
induction	NULL
.	NULL

Akata	NULL
cells	NULL
,	NULL
at	NULL
2	NULL
X	NULL
10Â°	NULL
cells/ml	NULL
,	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
100	NULL
ug	NULL
of	NULL
anti-human	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
;	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
for	NULL
3	NULL
h.	NULL
Adenovirus	NULL
construction	NULL
and	NULL
infection	NULL
.	NULL

The	NULL
Z	NULL
and	NULL
R	NULL
cDNAs	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
shuttle	NULL
vector	NULL
(	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
)	NULL
which	NULL
contains	NULL
a	NULL
loxP	NULL
EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
_	NULL
2389	NULL
site	NULL
,	NULL
the	NULL
left	NULL
adenovirus	NULL
terminal	NULL
repeat	NULL
,	NULL
and	NULL
a	NULL
packaging	NULL
signal	NULL
.	NULL

This	NULL
vector	NULL
was	NULL
recombined	NULL
(	NULL
in	NULL
a	NULL
cell	NULL
line	NULL
expressing	NULL
the	NULL
phage	NULL
P1	NULL
Cre	NULL
protein	NULL
)	NULL
into	NULL
the	NULL
loxP	NULL
site	NULL
of	NULL
an	NULL
adenovirus	NULL
lacking	NULL
the	NULL
E1	NULL
and	NULL
E3	NULL
genes	NULL
as	NULL
well	NULL
as	NULL
a	NULL
packaging	NULL
sequence	NULL
to	NULL
create	NULL
adenovirus-Z	NULL
and	NULL
adenovirus-R	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
81	NULL
)	NULL
.	NULL

A	NULL
control	NULL
vector	NULL
(	NULL
adenovirus-LacZ	NULL
)	NULL
,	NULL
containing	NULL
the	NULL
lacZ	NULL
gene	NULL
,	NULL
was	NULL
made	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
plated	NULL
at	NULL
a	NULL
cell	NULL
density	NULL
of	NULL
10Â°	NULL
cells	NULL
per	NULL
100-mm	NULL
plate	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
with	NULL
no	NULL
adenovirus	NULL
(	NULL
mock	NULL
infection	NULL
)	NULL
,	NULL
adenovirus-LacZ	NULL
,	NULL
adenovirus-R	NULL
,	NULL
or	NULL
adenovirus-Z	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
50	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
48	NULL
h	NULL
postinfection	NULL
.	NULL

Plasmids	NULL
.	NULL

The	NULL
CMV-Z	NULL
expression	NULL
vector	NULL
contains	NULL
the	NULL
Z	NULL
cDNA	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
immediate-early	NULL
promoter	NULL
in	NULL
the	NULL
pHD1013	NULL
vector	NULL
(	NULL
64	NULL
)	NULL
.	NULL

The	NULL
SV-Z	NULL
expression	NULL
vector	NULL
contains	NULL
a	NULL
genomic	NULL
clone	NULL
downstream	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
immediate-early	NULL
promoter	NULL
in	NULL
the	NULL
SVpIE	NULL
vector	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
Z311	NULL
expression	NULL
vector	NULL
contains	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
Z	NULL
in	NULL
which	NULL
amino	NULL
acid	NULL
185	NULL
is	NULL
altered	NULL
(	NULL
abolishing	NULL
DNA	NULL
binding	NULL
)	NULL
,	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
immediate-early	NULL
promoter	NULL
,	NULL
in	NULL
the	NULL
pHD1013	NULL
vector	NULL
(	NULL
28	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Z86-245	NULL
(	NULL
previously	NULL
referred	NULL
to	NULL
as	NULL
RAZAR	NULL
)	NULL
has	NULL
the	NULL
codons	NULL
for	NULL
amino	NULL
acids	NULL
2	NULL
to	NULL
86	NULL
deleted	NULL
(	NULL
gift	NULL
of	NULL
Joseph	NULL
Pagano	NULL
)	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Z	NULL
(	NULL
S186A	NULL
)	NULL
contains	NULL
a	NULL
genomic	NULL
clone	NULL
mutated	NULL
at	NULL
amino	NULL
acid	NULL
186	NULL
downstream	NULL
of	NULL
the	NULL
SV40	NULL
immediate-early	NULL
promoter	NULL
in	NULL
the	NULL
SVpIE	NULL
vector	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Z25-131	NULL
has	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
codons	NULL
for	NULL
the	NULL
first	NULL
24	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
and	NULL
is	NULL
downstream	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Z131-245	NULL
has	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
codons	NULL
for	NULL
the	NULL
first	NULL
130	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
and	NULL
is	NULL
downstream	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
7	NULL
)	NULL
.	NULL

ZA25-42	NULL
contains	NULL
the	NULL
Z	NULL
cDNA	NULL
with	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
codons	NULL
for	NULL
amino	NULL
acids	NULL
25	NULL
to	NULL
42	NULL
(	NULL
gift	NULL
of	NULL
Alain	NULL
Sergeant	NULL
)	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
immediate-early	NULL
promoter	NULL
in	NULL
the	NULL
pHD1013	NULL
vector	NULL
.	NULL

Zta	NULL
(	NULL
m12/13	NULL
)	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
Zm12/13	NULL
in	NULL
this	NULL
paper	NULL
,	NULL
contains	NULL
mutations	NULL
at	NULL
amino	NULL
acids	NULL
12	NULL
and	NULL
13	NULL
(	NULL
from	NULL
KF	NULL
to	NULL
AA	NULL
)	NULL
in	NULL
the	NULL
peDL-SRa296	NULL
vector	NULL
(	NULL
gift	NULL
of	NULL
Diane	NULL
Hayward	NULL
)	NULL
(	NULL
69	NULL
)	NULL
.	NULL

In	NULL
experiments	NULL
with	NULL
Zm12/13	NULL
,	NULL
a	NULL
plasmid	NULL
containing	NULL
wild-type	NULL
Z	NULL
in	NULL
the	NULL
peDL-SRa296	NULL
vector	NULL
was	NULL
used	NULL
(	NULL
69	NULL
)	NULL
.	NULL

PRTS-15	NULL
contains	NULL
R	NULL
downstream	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
in	NULL
the	NULL
pSGS	NULL
vector	NULL
(	NULL
gift	NULL
of	NULL
Diane	NULL
Hayward	NULL
)	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
vector	NULL
contains	NULL
the	NULL
PML	NULL
gene	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
in	NULL
the	NULL
CMX	NULL
vector	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
HA-SUMO-1	NULL
vector	NULL
contains	NULL
the	NULL
hemagglutinin	NULL
(	NULL
HA	NULL
)	NULL
-tagged	NULL
SUMO-1	NULL
gene	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
in	NULL
the	NULL
pHSS10B	NULL
vector	NULL
(	NULL
55	NULL
)	NULL
.	NULL

DNA	NULL
purification	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
purified	NULL
through	NULL
Qiagen	NULL
columns	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Qiagen	NULL
)	NULL
.	NULL

DNA	NULL
transfection	NULL
.	NULL

DNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
cells	NULL
by	NULL
electroporation	NULL
with	NULL
a	NULL
Zapper	NULL
electroporation	NULL
unit	NULL
(	NULL
Medical	NULL
Electronics	NULL
Shop	NULL
,	NULL
University	NULL
of	NULL
Wisconsin	NULL
)	NULL
at	NULL
1,500	NULL
V	NULL
as	NULL
described	NULL
(	NULL
76	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
prior	NULL
to	NULL
electroporation	NULL
.	NULL

Protein	NULL
preparation	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
ELB	NULL
buffer	NULL
(	NULL
0.25	NULL
M	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
NP-40	NULL
,	NULL
50	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7	NULL
]	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
protease	NULL
inhibitors	NULL
)	NULL
,	NULL
and	NULL
freeze-thawed	NULL
twice	NULL
.	NULL

The	NULL
lysed	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
used	NULL
for	NULL
immunoblot	NULL
analysis	NULL
.	NULL

For	NULL
SUMO-1-modified	NULL
proteins	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
a	NULL
1:3	NULL
mixture	NULL
of	NULL
buffer	NULL
I	NULL
(	NULL
5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
[	NULL
SDS	NULL
]	NULL
,	NULL
0.15	NULL
M	NULL
Tris-HCI	NULL
[	NULL
pH	NULL
6.8	NULL
]	NULL
,	NULL
30	NULL
%	NULL
glycerol	NULL
)	NULL
and	NULL
buffer	NULL
II	NULL
(	NULL
25	NULL
mM	NULL
Tris-HCI	NULL
[	NULL
pH	NULL
8.3	NULL
]	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
NP-40	NULL
,	NULL
0.5	NULL
%	NULL
deoxycholate	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
and	NULL
protease	NULL
inhibitors	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
briefly	NULL
sonicated	NULL
and	NULL
centrifuged	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
supernatant	NULL
was	NULL
used	NULL
for	NULL
immunoblot	NULL
analysis	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
was	NULL
performed	NULL
to	NULL
detect	NULL
the	NULL
PML	NULL
,	NULL
Z	NULL
,	NULL
and	NULL
HA-SUMO-1	NULL
proteins	NULL
as	NULL
follows	NULL
.	NULL

Briefly	NULL
,	NULL
10	NULL
to	NULL
100	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
loaded	NULL
in	NULL
each	NULL
lane	NULL
,	NULL
and	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
was	NULL
performed	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
transferred	NULL
onto	NULL
nitrocellulose	NULL
(	NULL
Protran	NULL
)	NULL
,	NULL
blocked	NULL
in	NULL
1	NULL
%	NULL
PBS-5	NULL
%	NULL
milk-0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
and	NULL
incubated	NULL
in	NULL
primary	NULL
antibody	NULL
for	NULL
1	NULL
to	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
or	NULL
overnight	NULL
at	NULL
4Â°C	NULL
(	NULL
monoclonal	NULL
anti-EBV	NULL
Zebra	NULL
[	NULL
1:100	NULL
]	NULL
from	NULL
Argene	NULL
;	NULL
monoclonal	NULL
anti-PML	NULL
[	NULL
PG-M3	NULL
]	NULL
[	NULL
1:100	NULL
]	NULL
from	NULL
Santa	NULL
Cruz	NULL
;	NULL
anti-HA	NULL
probe	NULL
[	NULL
Y-11	NULL
]	NULL
[	NULL
1:100	NULL
]	NULL
from	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
washed	NULL
in	NULL
PBS-0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
incubated	NULL
in	NULL
secondary	NULL
antibody	NULL
for	NULL
30	NULL
to	NULL
60	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
goat	NULL
anti-mouse	NULL
Ig-horseradish	NULL
peroxidase	NULL
[	NULL
1:10,000	NULL
]	NULL
conjugate	NULL
from	NULL
Promega	NULL
;	NULL
goat	NULL
anti-rabbit	NULL
Ig-horseradish	NULL
peroxidase	NULL
conjugate	NULL
[	NULL
1:10,000	NULL
]	NULL
from	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
the	NULL
results	NULL
were	NULL
visualized	NULL
with	NULL
the	NULL
ECL	NULL
chemiluminescence	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Immunocytochemistry	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
on	NULL
glass	NULL
coverslips	NULL
,	NULL
rinsed	NULL
in	NULL
1	NULL
%	NULL
Tris-saline	NULL
(	NULL
TS	NULL
;	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
8	NULL
]	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
)	NULL
,	NULL
and	NULL
fixed	NULL
in	NULL
100	NULL
%	NULL
methanol	NULL
for	NULL
10	NULL
min	NULL
at	NULL
-20Â°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
rehydrated	NULL
in	NULL
cold	NULL
1	NULL
%	NULL
TS	NULL
for	NULL
5	NULL
min	NULL
,	NULL
incubated	NULL
in	NULL
incubation	NULL
mix	NULL
(	NULL
1	NULL
%	NULL
TS	NULL
,	NULL
0.3	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
[	NULL
BSA	NULL
]	NULL
,	NULL
5	NULL
%	NULL
goat	NULL
serum	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
min	NULL
,	NULL
incubated	NULL
in	NULL
primary	NULL
antibody	NULL
diluted	NULL
in	NULL
incubation	NULL
mix	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
(	NULL
monoclonal	NULL
anti-EBV	NULL
Zebra	NULL
[	NULL
1:50	NULL
]	NULL
,	NULL
polyclonal	NULL
anti-Z	NULL
M47	NULL
[	NULL
1:500	NULL
]	NULL
,	NULL
from	NULL
Erik	NULL
Flemington	NULL
;	NULL
monoclonal	NULL
anti-PML	NULL
protein	NULL
[	NULL
PG-M3	NULL
]	NULL
[	NULL
1:100	NULL
]	NULL
,	NULL
from	NULL
Santa	NULL
Cruz	NULL
;	NULL
polyclonal	NULL
anti-PML	NULL
protein	NULL
[	NULL
1:1,000	NULL
]	NULL
,	NULL
from	NULL
Gary	NULL
Hayward	NULL
;	NULL
or	NULL
monoclonal	NULL
anti-EBV	NULL
R	NULL
[	NULL
1:50	NULL
]	NULL
from	NULL
Argene	NULL
)	NULL
.	NULL

2390	NULL
ADAMSON	NULL
AND	NULL
KENNEY	NULL
J	NULL
.	NULL

FIG	NULL
.	NULL

1	NULL
.	NULL

EBV	NULL
lytic	NULL
replication	NULL
disrupts	NULL
PML	NULL
bodies	NULL
.	NULL

EBV-positive	NULL
cells	NULL
(	NULL
D98/HE-R-1	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
plasmids	NULL
for	NULL
either	NULL
Z	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
R	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

At	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
immunostained	NULL
with	NULL
either	NULL
anti-Z	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
A	NULL
)	NULL
,	NULL
anti-R	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
anti-PML	NULL
protein	NULL
(	NULL
polyclonal	NULL
)	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
antibodies	NULL
.	NULL

Arrows	NULL
indicate	NULL
cells	NULL
that	NULL
are	NULL
positively	NULL
expressing	NULL
Z	NULL
or	NULL
R.	NULL
Cells	NULL
were	NULL
washed	NULL
four	NULL
times	NULL
with	NULL
1	NULL
%	NULL
TS-0.5	NULL
%	NULL
BSA	NULL
for	NULL
5	NULL
min	NULL
each	NULL
and	NULL
then	NULL
incubated	NULL
in	NULL
secondary	NULL
antibody	NULL
diluted	NULL
in	NULL
incubation	NULL
mix	NULL
for	NULL
45	NULL
min	NULL
at	NULL
37Â°C	NULL
(	NULL
goat	NULL
anti-mouse	NULL
Ig-fluorescein	NULL
isothiocyanate	NULL
conjugate	NULL
[	NULL
1:100	NULL
]	NULL
,	NULL
from	NULL
Sigma	NULL
;	NULL
goat	NULL
anti-rabbit	NULL
Ig-indocarbocyanine	NULL
conjugate	NULL
[	NULL
1:100	NULL
]	NULL
,	NULL
from	NULL
Jackson	NULL
Labs	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
as	NULL
before	NULL
,	NULL
mounted	NULL
in	NULL
Anti-fade	NULL
medium	NULL
(	NULL
Molecular	NULL
Probes	NULL
)	NULL
,	NULL
and	NULL
viewed	NULL
on	NULL
a	NULL
Zeiss	NULL
Axioskop	NULL
or	NULL
Zeiss	NULL
confocal	NULL
microscope	NULL
.	NULL

RESULTS	NULL
Lytic	NULL
EBV	NULL
replication	NULL
disperses	NULL
PML	NULL
bodies	NULL
.	NULL

Expression	NULL
of	NULL
either	NULL
the	NULL
EBV	NULL
Z	NULL
or	NULL
R	NULL
immediate-early	NULL
protein	NULL
in	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
is	NULL
sufficient	NULL
to	NULL
trigger	NULL
lytic	NULL
EBV	NULL
replication	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
43	NULL
,	NULL
65	NULL
,	NULL
67	NULL
,	NULL
68	NULL
,	NULL
75	NULL
,	NULL
81	NULL
,	NULL
82	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
lytic	NULL
EBV	NULL
replication	NULL
induces	NULL
disruption	NULL
of	NULL
PML	NULL
bodies	NULL
,	NULL
we	NULL
used	NULL
expression	NULL
vectors	NULL
to	NULL
express	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
proteins	NULL
in	NULL
the	NULL
latently	NULL
infected	NULL
EBV-positive	NULL
cell	NULL
line	NULL
D98/HE-R1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
that	NULL
are	NULL
positively	NULL
expressing	NULL
Z	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
there	NULL
is	NULL
a	NULL
coincident	NULL
dispersal	NULL
of	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
other	NULL
immediate-early	NULL
protein	NULL
,	NULL
R	NULL
,	NULL
also	NULL
induced	NULL
relocalization	NULL
of	NULL
PML	NULL
bodies	NULL
in	NULL
these	NULL
EBV-positive	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
repeated	NULL
several	NULL
times	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

Therefore	NULL
,	NULL
lytic	NULL
EBV	NULL
replication	NULL
induces	NULL
dispersal	NULL
of	NULL
PML	NULL
bodies	NULL
.	NULL

Z	NULL
but	NULL
not	NULL
R	NULL
expression	NULL
disperses	NULL
PML	NULL
bodies	NULL
.	NULL

The	NULL
two	NULL
other	NULL
herpesvirus	NULL
family	NULL
members	NULL
known	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
,	NULL
HSV-1	NULL
and	NULL
CMV	NULL
,	NULL
do	NULL
so	NULL
via	NULL
their	NULL
immediate-early	NULL
proteins	NULL
ICPO	NULL
and	NULL
IE1	NULL
,	NULL
respectively	NULL
(	NULL
3	NULL
,	NULL
23	NULL
,	NULL
40	NULL
,	NULL
46	NULL
,	NULL
57	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
an	NULL
EBV	NULL
immediate-early	NULL
protein	NULL
is	NULL
also	NULL
responsible	NULL
for	NULL
PML	NULL
body	NULL
relocalization	NULL
,	NULL
we	NULL
expressed	NULL
either	NULL
Z	NULL
or	NULL
R	NULL
in	NULL
EBV-negative	NULL
cells	NULL
and	NULL
examined	NULL
the	NULL
resulting	NULL
PML	NULL
body	NULL
distribution	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
Z	NULL
in	NULL
EBV-negative	NULL
HeLa	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
redistribution	NULL
of	NULL
PML	NULL
protein	NULL
from	NULL
PML	NULL
bodies	NULL
to	NULL
a	NULL
diffuse	NULL
microspeckled	NULL
pattern	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
expression	NULL
of	NULL
R	NULL
in	NULL
HeLa	NULL
cells	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
localization	NULL
of	NULL
PML	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
EBV	NULL
early	NULL
protein	NULL
BMRF1	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
PML	NULL
protein	NULL
localization	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
repeated	NULL
several	NULL
times	NULL
with	NULL
results	NULL
identical	NULL
to	NULL
those	NULL
presented	NULL
.	NULL

Therefore	NULL
,	NULL
Z	NULL
expression	NULL
is	NULL
sufficient	NULL
to	NULL
disrupt	NULL
PML	NULL
bodies	NULL
.	NULL

Transactivation	NULL
domain	NULL
of	NULL
Z	NULL
is	NULL
necessary	NULL
for	NULL
dispersal	NULL
of	NULL
PML	NULL
protein	NULL
.	NULL

The	NULL
Z	NULL
protein	NULL
has	NULL
functional	NULL
domains	NULL
for	NULL
transcriptional	NULL
transactivation	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
homodimeriza-tion	NULL
(	NULL
25	NULL
,	NULL
47	NULL
,	NULL
61	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
region	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
is	NULL
required	NULL
for	NULL
PML	NULL
protein	NULL
dispersal	NULL
,	NULL
we	NULL
expressed	NULL
various	NULL
Z	NULL
mutants	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
in	NULL
EBV-negative	NULL
HeLa	NULL
cells	NULL
and	NULL
examined	NULL
the	NULL
resulting	NULL
PML	NULL
protein	NULL
localization	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
first	NULL
half	NULL
of	NULL
Z	NULL
(	NULL
Z131-245	NULL
)	NULL
rendered	NULL
the	NULL
protein	NULL
unable	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

More	NULL
specifically	NULL
,	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
86	NULL
of	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
Z	NULL
are	NULL
necessary	NULL
for	NULL
PML	NULL
dispersal	NULL
(	NULL
Fig	NULL
.	NULL

4E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

ZA25-42	NULL
retained	NULL
the	NULL
ability	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

4G	NULL
and	NULL
H	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
first	NULL
24	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
(	NULL
Z25-245	NULL
)	NULL
partially	NULL
but	NULL
not	NULL
completely	NULL
blocked	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
protein	NULL
to	NULL
disrupt	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

41	NULL
and	NULL
J	NULL
)	NULL
.	NULL

Z	NULL
constructs	NULL
containing	NULL
mutations	NULL
within	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
Z	NULL
,	NULL
including	NULL
Z311	NULL
(	NULL
mutation	NULL
at	NULL
codon	NULL
185	NULL
which	NULL
renders	NULL
the	NULL
protein	NULL
unable	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
)	NULL
and	NULL
Z	NULL
(	NULL
S186A	NULL
)	NULL
(	NULL
mutation	NULL
at	NULL
codon	NULL
186	NULL
which	NULL
prevents	NULL
protein	NULL
from	NULL
inducing	NULL
lytic	NULL
EBV	NULL
replication	NULL
)	NULL
retained	NULL
the	NULL
ability	NULL
to	NULL
disrupt	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

4K	NULL
,	NULL
L	NULL
,	NULL
M	NULL
,	NULL
and	NULL
N	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
24	NULL
,	NULL
which	NULL
were	NULL
previously	NULL
shown	NULL
to	NULL
have	NULL
a	NULL
replication	NULL
function	NULL
distinct	NULL
from	NULL
the	NULL
Z	NULL
transcriptional	NULL
function	NULL
(	NULL
69	NULL
)	NULL
,	NULL
and	NULL
the	NULL
second	NULL
half	NULL
of	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
Z	NULL
(	NULL
amino	NULL
acids	NULL
42	NULL
to	NULL
86	NULL
)	NULL
are	NULL
necessary	NULL
for	NULL
Z	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
fully	NULL
.	NULL

However	NULL
,	NULL
direct	NULL
DNA	NULL
binding	NULL
is	NULL
not	NULL
required	NULL
.	NULL

Z	NULL
induces	NULL
loss	NULL
of	NULL
high-molecular-weight	NULL
isoforms	NULL
of	NULL
PML	NULL
protein	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
has	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
approximately	NULL
70	NULL
kDa	NULL
;	NULL
however	NULL
,	NULL
several	NULL
higher-molecular-weight	NULL
isoforms	NULL
of	NULL
PML	NULL
protein	NULL
exist	NULL
.	NULL

These	NULL
higher-molecular-weight	NULL
isoforms	NULL
are	NULL
modified	NULL
by	NULL
SUMO-1	NULL
,	NULL
a	NULL
small	NULL
ubiquitin-like	NULL
protein	NULL
that	NULL
is	NULL
covalently	NULL
linked	NULL
to	NULL
PML	NULL
protein	NULL
(	NULL
8	NULL
,	NULL
66	NULL
,	NULL
72	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
Z	NULL
disperses	NULL
PML	NULL
protein	NULL
by	NULL
inducing	NULL
a	NULL
loss	NULL
vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
_	NULL
2391	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Z	NULL
but	NULL
not	NULL
R	NULL
expression	NULL
disrupts	NULL
PML	NULL
bodies	NULL
.	NULL

EBV-negative	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
plasmids	NULL
for	NULL
either	NULL
Z	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
R	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

At	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
immunostained	NULL
with	NULL
either	NULL
anti-Z	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
A	NULL
)	NULL
,	NULL
anti-R	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
anti-PML	NULL
protein	NULL
(	NULL
polyclonal	NULL
)	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
antibodies	NULL
.	NULL

of	NULL
SUMO-1-modified	NULL
PML	NULL
protein	NULL
isoforms	NULL
,	NULL
we	NULL
expressed	NULL
Z	NULL
in	NULL
EBV-negative	NULL
A549	NULL
cells	NULL
via	NULL
an	NULL
adenovirus	NULL
construct	NULL
and	NULL
performed	NULL
an	NULL
immunoblot	NULL
with	NULL
an	NULL
anti-PML	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Cells	NULL
that	NULL
expressed	NULL
Z	NULL
but	NULL
not	NULL
the	NULL
control	NULL
protein	NULL
LacZ	NULL
lost	NULL
the	NULL
high-molecular-weight	NULL
forms	NULL
of	NULL
PML	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

R	NULL
expression	NULL
did	NULL
not	NULL
affect	NULL
PML	NULL
protein	NULL
levels	NULL
or	NULL
SUMO-1	NULL
modification	NULL
.	NULL

This	NULL
Z-induced	NULL
loss	NULL
of	NULL
SUMO-1-modified	NULL
PML	NULL
protein	NULL
isoforms	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
HeLa	NULL
and	NULL
D98/HE-R1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Z	NULL
is	NULL
modified	NULL
by	NULL
SUMO-1	NULL
.	NULL

The	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
targets	NULL
PML	NULL
protein	NULL
to	NULL
nuclear	NULL
bodies	NULL
(	NULL
60	NULL
,	NULL
86	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
Z	NULL
is	NULL
modified	NULL
by	NULL
SUMO-1	NULL
,	NULL
we	NULL
expressed	NULL
Z	NULL
and	NULL
HA-tagged	NULL
SUMO-1	NULL
proteins	NULL
in	NULL
DG75	NULL
cells	NULL
,	NULL
harvested	NULL
these	NULL
cells	NULL
in	NULL
a	NULL
rapidly	NULL
denaturing	NULL
buffer	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
transactivation	NULL
DNA	NULL
dim	NULL
.	NULL

Lennon	NULL
)	NULL
Poy	NULL
a	NULL
1	NULL
25	NULL
42	NULL
86	NULL
131	NULL
228	NULL
_	NULL
245aa	NULL
170	NULL
198	NULL
Z	NULL
2131-245	NULL
286-245	NULL
ZA25-42	NULL
725-245	NULL
Z311	NULL
m	NULL
Z	NULL
(	NULL
S186A	NULL
)	NULL
N	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Structures	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
Z	NULL
proteins	NULL
.	NULL

The	NULL
transactivation	NULL
(	NULL
hatched	NULL
)	NULL
,	NULL
DNA-binding	NULL
(	NULL
DNA	NULL
;	NULL
black	NULL
)	NULL
,	NULL
and	NULL
dimerization	NULL
(	NULL
dim	NULL
.	NULL

;	NULL
stippled	NULL
)	NULL
domains	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
amino	NULL
acid	NULL
(	NULL
aa	NULL
)	NULL
numbers	NULL
are	NULL
noted	NULL
at	NULL
the	NULL
top	NULL
.	NULL

X	NULL
,	NULL
mutated	NULL
amino	NULL
acid	NULL
.	NULL

previously	NULL
to	NULL
prevent	NULL
loss	NULL
of	NULL
SUMO-1	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
performed	NULL
immunoblot	NULL
analysis	NULL
with	NULL
anti-Z	NULL
and	NULL
anti-HA	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Using	NULL
these	NULL
harvesting	NULL
conditions	NULL
,	NULL
the	NULL
anti-Z	NULL
antibody	NULL
detected	NULL
at	NULL
least	NULL
two	NULL
larger	NULL
bands	NULL
(	NULL
at	NULL
approximately	NULL
50	NULL
and	NULL
66	NULL
kDa	NULL
)	NULL
,	NULL
and	NULL
possibly	NULL
a	NULL
third	NULL
larger	NULL
band	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
normal	NULL
Z	NULL
band	NULL
(	NULL
35	NULL
kDa	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
left	NULL
panel	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Increasing	NULL
amounts	NULL
of	NULL
transfected	NULL
HA-SUMO-1	NULL
increased	NULL
the	NULL
intensity	NULL
of	NULL
these	NULL
larger	NULL
bands	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
increased	NULL
levels	NULL
of	NULL
SUMO-1	NULL
lead	NULL
to	NULL
increased	NULL
levels	NULL
of	NULL
Z/SUMO-1	NULL
.	NULL

To	NULL
ensure	NULL
that	NULL
the	NULL
50	NULL
and	NULL
66-kDa	NULL
Z	NULL
bands	NULL
were	NULL
indeed	NULL
modified	NULL
by	NULL
the	NULL
HA-SUMO-1	NULL
protein	NULL
,	NULL
we	NULL
probed	NULL
an	NULL
identical	NULL
blot	NULL
with	NULL
anti-HA	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Lanes	NULL
10	NULL
to	NULL
12	NULL
clearly	NULL
show	NULL
that	NULL
the	NULL
50-	NULL
and	NULL
66-kDa	NULL
bands	NULL
are	NULL
HA-SUMO-1-modified	NULL
Z	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Z	NULL
is	NULL
SUMO-1	NULL
modified	NULL
and	NULL
that	NULL
there	NULL
are	NULL
at	NULL
least	NULL
two	NULL
forms	NULL
of	NULL
SUMO-1-modified	NULL
Z	NULL
.	NULL

We	NULL
subsequently	NULL
used	NULL
the	NULL
same	NULL
technique	NULL
to	NULL
map	NULL
the	NULL
do-main	NULL
(	NULL
s	NULL
)	NULL
of	NULL
Z	NULL
that	NULL
is	NULL
required	NULL
for	NULL
SUMO-1	NULL
modification	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
cotransfection	NULL
of	NULL
the	NULL
HA-SUMO-1	NULL
plasmid	NULL
with	NULL
a	NULL
series	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
Z	NULL
plasmids	NULL
induced	NULL
SUMO-1	NULL
modification	NULL
of	NULL
all	NULL
constructs	NULL
containing	NULL
the	NULL
first	NULL
24	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
but	NULL
did	NULL
not	NULL
modify	NULL
any	NULL
mutant	NULL
in	NULL
which	NULL
these	NULL
residues	NULL
were	NULL
deleted	NULL
.	NULL

Since	NULL
there	NULL
is	NULL
only	NULL
one	NULL
lysine	NULL
in	NULL
the	NULL
first	NULL
24	NULL
amino	NULL
acids	NULL
of	NULL
Z	NULL
(	NULL
residue	NULL
12	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
a	NULL
Z	NULL
construct	NULL
that	NULL
contained	NULL
mutations	NULL
at	NULL
amino	NULL
acids	NULL
12	NULL
and	NULL
13	NULL
and	NULL
found	NULL
that	NULL
this	NULL
mutant	NULL
did	NULL
not	NULL
become	NULL
SUMO-1	NULL
modified	NULL
.	NULL

Therefore	NULL
,	NULL
Z	NULL
is	NULL
SUMO-1	NULL
modified	NULL
on	NULL
the	NULL
lysine	NULL
residing	NULL
at	NULL
amino	NULL
acid	NULL
position	NULL
12	NULL
.	NULL

Z	NULL
and	NULL
PML	NULL
protein	NULL
compete	NULL
for	NULL
limiting	NULL
levels	NULL
of	NULL
SUMO-1	NULL
.	NULL

As	NULL
evident	NULL
from	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
Z	NULL
is	NULL
very	NULL
efficiently	NULL
modified	NULL
by	NULL
SUMO-1	NULL
.	NULL

If	NULL
SUMO-1	NULL
is	NULL
limiting	NULL
in	NULL
cells	NULL
,	NULL
then	NULL
a	NULL
protein	NULL
that	NULL
is	NULL
strongly	NULL
modified	NULL
by	NULL
SUMO-1	NULL
could	NULL
potentially	NULL
disperse	NULL
PML	NULL
protein	NULL
by	NULL
competing	NULL
with	NULL
PML	NULL
protein	NULL
for	NULL
limiting	NULL
levels	NULL
of	NULL
SUMO-1	NULL
protein	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
Z	NULL
is	NULL
able	NULL
to	NULL
compete	NULL
2392	NULL
ADAMSON	NULL
AND	NULL
KENNEY	NULL
anti-Z	NULL
anti-PML	NULL
7131-245	NULL
won	NULL
786-245	NULL
c	NULL
``	NULL
ZA25-42	NULL
-	NULL
ZA25-42	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
_	NULL
2393	NULL
anti-PML	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Mapping	NULL
the	NULL
region	NULL
of	NULL
Z	NULL
required	NULL
for	NULL
PML	NULL
body	NULL
dispersion	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

At	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
immunostained	NULL
with	NULL
anti-Z	NULL
(	NULL
polyclonal	NULL
)	NULL
antibody	NULL
(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
E	NULL
,	NULL
G	NULL
,	NULL
I	NULL
,	NULL
K	NULL
,	NULL
and	NULL
M	NULL
)	NULL
and	NULL
anti-PML	NULL
protein	NULL
(	NULL
monoclonal	NULL
)	NULL
antibody	NULL
(	NULL
B	NULL
,	NULL
D	NULL
,	NULL
F	NULL
,	NULL
H	NULL
,	NULL
J	NULL
,	NULL
L	NULL
,	NULL
and	NULL
N	NULL
)	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
wild-type	NULL
Z	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
Z131-245	NULL
.	NULL

(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
286-245	NULL
.	NULL

(	NULL
G	NULL
and	NULL
H	NULL
)	NULL
ZA25-42	NULL
(	NULL
I	NULL
and	NULL
J	NULL
)	NULL
225-245	NULL
.	NULL

(	NULL
K	NULL
and	NULL
L	NULL
)	NULL
Z311	NULL
.	NULL

(	NULL
M	NULL
and	NULL
N	NULL
)	NULL
Z	NULL
(	NULL
S186A	NULL
)	NULL
.	NULL

Arrows	NULL
point	NULL
to	NULL
cells	NULL
that	NULL
are	NULL
positively	NULL
expressing	NULL
Z.	NULL
with	NULL
PML	NULL
protein	NULL
for	NULL
SUMO-1	NULL
modification	NULL
,	NULL
we	NULL
expressed	NULL
PML	NULL
protein	NULL
and	NULL
HA-SUMO-1	NULL
,	NULL
with	NULL
or	NULL
without	NULL
Z	NULL
,	NULL
in	NULL
DG75	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
so	NULL
as	NULL
to	NULL
preserve	NULL
SUMO-1	NULL
modification	NULL
,	NULL
and	NULL
we	NULL
performed	NULL
immunoblot	NULL
analysis	NULL
with	NULL
an	NULL
anti-HA	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

The	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
was	NULL
decreased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Z	NULL
(	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
,	NULL
while	NULL
the	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
remained	NULL
unchanged	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML	NULL
protein	NULL
(	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

When	NULL
the	NULL
level	NULL
of	NULL
cotransfected	NULL
HA-SUMO-1	NULL
plasmid	NULL
was	NULL
increased	NULL
to	NULL
10	NULL
ug	NULL
,	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Z	NULL
was	NULL
partially	NULL
rescued	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
total	NULL
level	NULL
of	NULL
PML	NULL
protein	NULL
was	NULL
slightly	NULL
decreased	NULL
by	NULL
Z	NULL
.	NULL

A	NULL
decrease	NULL
in	NULL
total	NULL
PML	NULL
protein	NULL
levels	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Z	NULL
is	NULL
not	NULL
unexpected	NULL
,	NULL
however	NULL
,	NULL
since	NULL
Fig	NULL
.	NULL

7B	NULL
shows	NULL
that	NULL
SUMO-1	NULL
2394	NULL
ADAMSON	NULL
AND	NULL
KENNEY	NULL
N	NULL
3	NULL
8	NULL
H4	NULL
N	NULL
%	NULL
=	NULL
he	NULL
Milks	NULL
)	NULL
he	NULL
Â§	NULL
_	NULL
<	NULL
<	NULL
<	NULL
wor	NULL
[	NULL
%	NULL
PML/SUMO-1	NULL
66	NULL
kD	NULL
-	NULL
<	NULL
a	NULL
Â»	NULL
<	NULL
p	NULL
<	NULL
mag	NULL
69	NULL
``	NULL
<	NULL
+	NULL
PML	NULL
t6	NULL
-	NULL
#	NULL
1	NULL
-	NULL
2	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Z	NULL
expression	NULL
induces	NULL
a	NULL
loss	NULL
of	NULL
PML	NULL
protein	NULL
isoforms	NULL
.	NULL

EBV-negative	NULL
A549	NULL
cells	NULL
were	NULL
mock	NULL
infected	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
infected	NULL
with	NULL
an	NULL
adenovirus	NULL
expressing	NULL
either	NULL
LacZ	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
Z	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
R	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
postinfection	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-PML	NULL
protein	NULL
monoclonal	NULL
antibody	NULL
.	NULL

PML	NULL
isoforms	NULL
lost	NULL
after	NULL
Z	NULL
expression	NULL
are	NULL
indicated	NULL
by	NULL
asterisks	NULL
.	NULL

greatly	NULL
stabilizes	NULL
PML	NULL
protein	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
the	NULL
Z	NULL
SUMO-1	NULL
modification	NULL
site	NULL
,	NULL
lysine	NULL
12	NULL
,	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
PML	NULL
protein	NULL
SUMO-1	NULL
modification	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
level	NULL
of	NULL
SUMO-1	NULL
is	NULL
limiting	NULL
in	NULL
cells	NULL
and	NULL
that	NULL
Z	NULL
out-competes	NULL
PML	NULL
protein	NULL
for	NULL
SUMO-1	NULL
modification	NULL
.	NULL

Loss	NULL
of	NULL
the	NULL
SUMO-1	NULL
modification	NULL
site	NULL
of	NULL
Z	NULL
does	NULL
not	NULL
prevent	NULL
PML	NULL
body	NULL
disruption	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
is	NULL
required	NULL
for	NULL
the	NULL
disruption	NULL
of	NULL
PML	NULL
bodies	NULL
,	NULL
we	NULL
expressed	NULL
the	NULL
Z	NULL
mutant	NULL
lacking	NULL
the	NULL
SUMO-1	NULL
site	NULL
,	NULL
Zm12/13	NULL
,	NULL
in	NULL
HeLa	NULL
cells	NULL
and	NULL
performed	NULL
immunocytochemistry	NULL
to	NULL
determine	NULL
the	NULL
localization	NULL
of	NULL
PML	NULL
protein	NULL
in	NULL
these	NULL
transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
the	NULL
Zm12/13	NULL
mutant	NULL
retained	NULL
the	NULL
ability	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
while	NULL
competition	NULL
for	NULL
SUMO-1	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
Z-induced	NULL
PML	NULL
body	NULL
dispersion	NULL
,	NULL
Z	NULL
must	NULL
also	NULL
use	NULL
another	NULL
mechanism	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
.	NULL

Induction	NULL
of	NULL
lytic	NULL
replication	NULL
in	NULL
Akata	NULL
cells	NULL
leads	NULL
to	NULL
rapid	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
lytic	NULL
replication	NULL
would	NULL
yield	NULL
levels	NULL
of	NULL
SUMO-1-modified	NULL
Z	NULL
comparable	NULL
to	NULL
the	NULL
levels	NULL
obtained	NULL
with	NULL
transfected	NULL
plasmids	NULL
,	NULL
we	NULL
induced	NULL
EBV-positive	NULL
Akata	NULL
cells	NULL
to	NULL
undergo	NULL
lytic	NULL
replication	NULL
via	NULL
cross-linking	NULL
of	NULL
the	NULL
surface	NULL
IgG	NULL
by	NULL
anti-IgG	NULL
.	NULL

Three	NULL
hours	NULL
after	NULL
in-duction	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
so	NULL
as	NULL
to	NULL
preserve	NULL
SUMO-1	NULL
modification	NULL
,	NULL
and	NULL
immunoblot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
anti-Z	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

While	NULL
control	NULL
cells	NULL
(	NULL
no	NULL
anti-IgG	NULL
)	NULL
did	NULL
not	NULL
express	NULL
Z	NULL
,	NULL
the	NULL
anti-IgG-treated	NULL
cells	NULL
expressed	NULL
Z	NULL
as	NULL
well	NULL
as	NULL
higher-molecular-weight	NULL
forms	NULL
of	NULL
Z	NULL
corresponding	NULL
to	NULL
SUMO-1-modified	NULL
species	NULL
.	NULL

Therefore	NULL
,	NULL
physiological	NULL
levels	NULL
of	NULL
Z	NULL
and	NULL
SUMO-1	NULL
are	NULL
sufficient	NULL
to	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
SUMO-1-modified	NULL
Z	NULL
.	NULL

DISCUSSION	NULL
The	NULL
EBV	NULL
immediate-early	NULL
protein	NULL
Z	NULL
is	NULL
required	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
EBV	NULL
early	NULL
genes	NULL
and	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
replication	NULL
mediated	NULL
through	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
oriLyt	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
direct	NULL
roles	NULL
in	NULL
lytic	NULL
viral	NULL
replica	NULL
J.	NULL
tion	NULL
,	NULL
increasing	NULL
evidence	NULL
suggests	NULL
that	NULL
Z	NULL
manipulates	NULL
the	NULL
host	NULL
cell	NULL
environment	NULL
through	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
mechanisms	NULL
,	NULL
presumably	NULL
to	NULL
provide	NULL
favorable	NULL
conditions	NULL
for	NULL
viral	NULL
replication	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Z	NULL
inhibits	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
12	NULL
)	NULL
,	NULL
activates	NULL
the	NULL
p38	NULL
kinase	NULL
and	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
signaling	NULL
cascades	NULL
(	NULL
1	NULL
)	NULL
,	NULL
and	NULL
alters	NULL
p53	NULL
(	NULL
84	NULL
)	NULL
and	NULL
CBP	NULL
function	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
the	NULL
Z	NULL
protein	NULL
also	NULL
induces	NULL
dispersion	NULL
of	NULL
nuclear	NULL
PML	NULL
bodies	NULL
,	NULL
an	NULL
ability	NULL
it	NULL
shares	NULL
with	NULL
at	NULL
least	NULL
two	NULL
other	NULL
immediate-early	NULL
proteins	NULL
in	NULL
the	NULL
herpesvirus	NULL
family	NULL
.	NULL

PML	NULL
body	NULL
dispersion	NULL
by	NULL
Z	NULL
requires	NULL
amino	NULL
acids	NULL
1	NULL
through	NULL
86	NULL
,	NULL
containing	NULL
the	NULL
Z	NULL
transactivation	NULL
domain	NULL
and	NULL
an	NULL
essential	NULL
replication	NULL
function	NULL
,	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
loss	NULL
of	NULL
PML	NULL
protein	NULL
SUMO-1	NULL
modification	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
Z	NULL
is	NULL
SUMO-1	NULL
modified	NULL
over	NULL
residue	NULL
12	NULL
,	NULL
suggesting	NULL
that	NULL
SUMO-1	NULL
modification	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
targeting	NULL
Z	NULL
to	NULL
specific	NULL
domains	NULL
within	NULL
the	NULL
nucleus	NULL
or	NULL
moderating	NULL
its	NULL
stability	NULL
or	NULL
protein-protein	NULL
interac-tions	NULL
.	NULL

SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
may	NULL
also	NULL
provide	NULL
a	NULL
mechanism	NULL
for	NULL
PML	NULL
body	NULL
dispersion	NULL
,	NULL
since	NULL
Z	NULL
competes	NULL
with	NULL
PML	NULL
protein	NULL
for	NULL
SUMO-1	NULL
.	NULL

However	NULL
,	NULL
unmodified	NULL
Z	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
,	NULL
indicating	NULL
that	NULL
another	NULL
mechanism	NULL
must	NULL
also	NULL
exist	NULL
for	NULL
PML	NULL
body	NULL
dispersion	NULL
.	NULL

Given	NULL
that	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
86	NULL
totally	NULL
prevents	NULL
dispersal	NULL
of	NULL
PML	NULL
bodies	NULL
by	NULL
Z	NULL
while	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
25	NULL
only	NULL
partially	NULL
prevents	NULL
dispersion	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
transcriptional	NULL
activator	NULL
region	NULL
of	NULL
Z	NULL
encodes	NULL
a	NULL
function	NULL
(	NULL
as	NULL
yet	NULL
undefined	NULL
)	NULL
required	NULL
for	NULL
full	NULL
PML	NULL
body	NULL
dispersion	NULL
.	NULL

PML	NULL
bodies	NULL
have	NULL
become	NULL
an	NULL
increasingly	NULL
intense	NULL
area	NULL
of	NULL
study	NULL
because	NULL
,	NULL
although	NULL
their	NULL
specific	NULL
function	NULL
remains	NULL
uncer-tain	NULL
,	NULL
they	NULL
clearly	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
tumor	NULL
suppression	NULL
.	NULL

PML	NULL
bodies	NULL
are	NULL
made	NULL
up	NULL
of	NULL
several	NULL
proteins	NULL
,	NULL
some	NULL
of	NULL
which	NULL
have	NULL
known	NULL
functions	NULL
(	NULL
CBP	NULL
and	NULL
Rb	NULL
)	NULL
,	NULL
and	NULL
some	NULL
of	NULL
which	NULL
have	NULL
unknown	NULL
functions	NULL
(	NULL
Sp100	NULL
and	NULL
PML	NULL
protein	NULL
)	NULL
.	NULL

Since	NULL
some	NULL
of	NULL
the	NULL
components	NULL
are	NULL
transcriptional	NULL
regulators	NULL
and	NULL
PML	NULL
protein	NULL
itself	NULL
is	NULL
structurally	NULL
similar	NULL
to	NULL
a	NULL
transcription	NULL
factor	NULL
,	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
PML	NULL
bodies	NULL
play	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
cellular	NULL
transcription	NULL
.	NULL

Although	NULL
PML	NULL
bodies	NULL
themselves	NULL
are	NULL
devoid	NULL
of	NULL
any	NULL
nucleic	NULL
acid	NULL
,	NULL
nucleic	NULL
acids	NULL
can	NULL
be	NULL
found	NULL
along	NULL
their	NULL
periphery	NULL
(	NULL
9	NULL
)	NULL
.	NULL

SUMO-1	NULL
is	NULL
another	NULL
component	NULL
of	NULL
PML	NULL
bodies	NULL
.	NULL

SUMO-1	NULL
is	NULL
found	NULL
covalently	NULL
attached	NULL
to	NULL
at	NULL
least	NULL
two	NULL
PML	NULL
body	NULL
proteins	NULL
,	NULL
PML	NULL
and	NULL
S	NULL
$	NULL
p100	NULL
.	NULL

Although	NULL
structurally	NULL
similar	NULL
to	NULL
ubiquitin	NULL
,	NULL
SUMO-1	NULL
does	NULL
not	NULL
target	NULL
proteins	NULL
for	NULL
degradation	NULL
.	NULL

Instead	NULL
,	NULL
SUMO-1	NULL
stabilizes	NULL
proteins	NULL
and	NULL
can	NULL
act	NULL
to	NULL
guide	NULL
them	NULL
to	NULL
their	NULL
appropriate	NULL
locations	NULL
within	NULL
the	NULL
nucleus	NULL
.	NULL

The	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
appears	NULL
to	NULL
be	NULL
of	NULL
utmost	NULL
importance-PML	NULL
protein	NULL
must	NULL
be	NULL
SUMO-1	NULL
modified	NULL
in	NULL
order	NULL
to	NULL
reside	NULL
within	NULL
PML	NULL
bodies	NULL
,	NULL
and	NULL
if	NULL
PML	NULL
protein	NULL
is	NULL
not	NULL
present	NULL
in	NULL
these	NULL
bodies	NULL
,	NULL
other	NULL
PML	NULL
body	NULL
members	NULL
do	NULL
not	NULL
localize	NULL
properly	NULL
(	NULL
86	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
PML	NULL
protein	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
main	NULL
organizer	NULL
of	NULL
the	NULL
PML	NULL
body	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
in	NULL
this	NULL
study	NULL
that	NULL
EBV	NULL
lytic	NULL
replication	NULL
disperses	NULL
PML	NULL
bodies	NULL
,	NULL
transforming	NULL
nuclear	NULL
dots	NULL
into	NULL
tiny	NULL
microspeckles	NULL
.	NULL

When	NULL
either	NULL
immediate-early	NULL
protein	NULL
,	NULL
Z	NULL
or	NULL
R	NULL
,	NULL
is	NULL
expressed	NULL
in	NULL
cells	NULL
latently	NULL
infected	NULL
with	NULL
EBV	NULL
,	NULL
PML	NULL
protein	NULL
becomes	NULL
dispersed	NULL
,	NULL
presumably	NULL
because	NULL
expression	NULL
of	NULL
either	NULL
protein	NULL
activates	NULL
the	NULL
entire	NULL
EBV	NULL
lytic	NULL
cascade	NULL
.	NULL

In	NULL
EBV-positive	NULL
cells	NULL
,	NULL
the	NULL
redistributed	NULL
protein	NULL
appears	NULL
to	NULL
form	NULL
larger	NULL
aggregates	NULL
than	NULL
in	NULL
EBV-negative	NULL
cells	NULL
,	NULL
potentially	NULL
due	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
EBV	NULL
replication	NULL
centers	NULL
containing	NULL
PML	NULL
protein	NULL
(	NULL
11	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
EBV-negative	NULL
cells	NULL
,	NULL
only	NULL
Z	NULL
is	NULL
capable	NULL
of	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
-	NULL
2395	NULL
A	NULL
0	NULL
0	NULL
2	NULL
-	NULL
HaSUmMoA	NULL
_	NULL
3	NULL
_	NULL
Ha-SUMO-1	NULL
5	NULL
o	NULL
5	NULL
oa	NULL
0	NULL
<	NULL
8	NULL
Â«	NULL
@	NULL
2	NULL
Am	NULL
nom	NULL
on-	NULL
2	NULL
#	NULL
non	NULL
N	NULL
Nn	NULL
66	NULL
kD-	NULL
woe	NULL
wo	NULL
cmm	NULL
|	NULL
<	NULL
46	NULL
kD-	NULL
-_	NULL
__	NULL
aas	NULL
--	NULL
ev	NULL
Gimp	NULL
|	NULL
<	NULL
&	NULL
-	NULL
Â»	NULL
-O	NULL
+Z	NULL
Io	NULL
2	NULL
30	NULL
40	NULL
50	NULL
6000	NULL
70	NULL
8	NULL
%	NULL
0	NULL
9	NULL
10	NULL
I1	NULL
)	NULL
12	NULL
anti-Z	NULL
antibody	NULL
anti-HA	NULL
antibody	NULL
B	NULL
+	NULL
HA-SUMO-1	NULL
|	NULL
2	NULL
%	NULL
$	NULL
g	NULL
g	NULL
|	NULL
5	NULL
a	NULL
4	NULL
2	NULL
a	NULL
g	NULL
bs	NULL
``	NULL
mo	NULL
wo	NULL
on	NULL
3	NULL
w	NULL
$	NULL
~a	NULL
Â§	NULL
Â§	NULL
Â§	NULL
Â§	NULL
Â§	NULL
66	NULL
kD-	NULL
anti-HA	NULL
tag	NULL
-	NULL
~-	NULL
eme	NULL
_-_	NULL
||	NULL
<	NULL
]	NULL
Z-SUMO-1	NULL
46	NULL
kD-	NULL
teus	NULL
114	NULL
Io	NULL
2	NULL
3Â°	NULL
400500	NULL
6007	NULL
46	NULL
kD	NULL
anti-Z	NULL
f	NULL
30	NULL
kD-	NULL
meas	NULL
-	NULL
--	NULL
-	NULL
__/	NULL
J	NULL
Z	NULL
Â«	NULL
smi	NULL
.	NULL

diac	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Z	NULL
is	NULL
modified	NULL
by	NULL
SUMO-1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EBV	NULL
-negative	NULL
DG75	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
vector	NULL
,	NULL
HA-SUMO-1	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
,	NULL
Z	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
,	NULL
or	NULL
Z	NULL
(	NULL
10	NULL
pug	NULL
)	NULL
plus	NULL
HA-SUMO-1	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
or	NULL
10	NULL
pg	NULL
)	NULL
expression	NULL
plasmids	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
using	NULL
conditions	NULL
which	NULL
preserve	NULL
SUMO-1	NULL
modification	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-Z	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
anti-HA	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
antibodies	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
HA-SUMO-1-modified	NULL
Z	NULL
proteins	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-negative	NULL
DG75	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
pg	NULL
of	NULL
HA-SUMO-1	NULL
plus	NULL
10	NULL
pg	NULL
of	NULL
either	NULL
vector	NULL
,	NULL
Z	NULL
,	NULL
Zm12/13	NULL
,	NULL
225-245	NULL
,	NULL
Z131-245	NULL
,	NULL
ZA25-42	NULL
,	NULL
or	NULL
Z86-245	NULL
expression	NULL
plasmids	NULL
.	NULL

Zm12/13	NULL
contains	NULL
mutations	NULL
that	NULL
alter	NULL
amino	NULL
acids	NULL
12	NULL
and	NULL
13	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
using	NULL
conditions	NULL
which	NULL
preserve	NULL
SUMO-1	NULL
modification	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-HA	NULL
(	NULL
monoclonal	NULL
)	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
or	NULL
anti-Z	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
antibodies	NULL
.	NULL

dispersing	NULL
PML	NULL
bodies	NULL
.	NULL

Therefore	NULL
,	NULL
R	NULL
likely	NULL
indirectly	NULL
disperses	NULL
PML	NULL
bodies	NULL
in	NULL
EBV-positive	NULL
cells	NULL
by	NULL
activating	NULL
the	NULL
expression	NULL
of	NULL
Z	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
Z	NULL
is	NULL
SUMO-1	NULL
modified	NULL
and	NULL
that	NULL
at	NULL
least	NULL
two	NULL
different	NULL
SUMO-1-modified	NULL
isoforms	NULL
exist	NULL
.	NULL

Since	NULL
the	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
is	NULL
responsible	NULL
for	NULL
its	NULL
localization	NULL
into	NULL
discrete	NULL
nuclear	NULL
bodies	NULL
,	NULL
SUMO-1	NULL
modification	NULL
may	NULL
likewise	NULL
target	NULL
Z	NULL
to	NULL
PML	NULL
bodies	NULL
.	NULL

We	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
show	NULL
that	NULL
Z	NULL
colocalizes	NULL
with	NULL
PML	NULL
bodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
transient	NULL
localization	NULL
of	NULL
Z	NULL
into	NULL
PML	NULL
bodies	NULL
does	NULL
occur	NULL
prior	NULL
to	NULL
the	NULL
disruption	NULL
of	NULL
PML	NULL
bodies	NULL
.	NULL

In	NULL
many	NULL
respects	NULL
,	NULL
our	NULL
findings	NULL
here	NULL
are	NULL
reminiscent	NULL
of	NULL
previous	NULL
reports	NULL
regarding	NULL
the	NULL
effects	NULL
of	NULL
HSV-1	NULL
and	NULL
CMV	NULL
on	NULL
PML	NULL
bodies	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
HSV-1	NULL
,	NULL
the	NULL
immediate-early	NULL
protein	NULL
ICPO	NULL
,	NULL
like	NULL
Z	NULL
,	NULL
disperses	NULL
PML	NULL
bodies	NULL
.	NULL

In	NULL
cells	NULL
infected	NULL
with	NULL
intact	NULL
HSV	NULL
,	NULL
new	NULL
nuclear	NULL
foci	NULL
appear	NULL
after	NULL
PML	NULL
bodies	NULL
are	NULL
disrupted	NULL
,	NULL
and	NULL
these	NULL
new	NULL
foci	NULL
function	NULL
as	NULL
HSV-1	NULL
replication	NULL
compartments	NULL
that	NULL
contain	NULL
HSV-1	NULL
replication	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
PML	NULL
protein	NULL
(	NULL
11	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
PML	NULL
protein	NULL
in	NULL
viral	NULL
replication	NULL
.	NULL

CMV	NULL
also	NULL
disrupts	NULL
PML	NULL
bodies	NULL
shortly	NULL
after	NULL
infection	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
CMV	NULL
,	NULL
the	NULL
IE1	NULL
protein	NULL
is	NULL
targeted	NULL
to	NULL
and	NULL
disperses	NULL
PML	NULL
bodies	NULL
,	NULL
possibly	NULL
through	NULL
a	NULL
mechanism	NULL
involving	NULL
direct	NULL
protein-protein	NULL
interactions	NULL
between	NULL
IE1	NULL
and	NULL
PML	NULL
protein	NULL
(	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
CMV	NULL
IE2	NULL
protein	NULL
is	NULL
also	NULL
targeted	NULL
to	NULL
but	NULL
does	NULL
not	NULL
disperse	NULL
PML	NULL
bodies	NULL
.	NULL

Similar	NULL
to	NULL
HSV-1	NULL
,	NULL
CMV	NULL
replication	NULL
compartments	NULL
(	NULL
which	NULL
contain	NULL
IE2	NULL
as	NULL
well	NULL
as	NULL
several	NULL
other	NULL
essential	NULL
viral	NULL
replication	NULL
proteins	NULL
)	NULL
subsequently	NULL
form	NULL
adjacent	NULL
to	NULL
the	NULL
former	NULL
PML	NULL
bodies	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Another	NULL
striking	NULL
similarity	NULL
is	NULL
the	NULL
ability	NULL
of	NULL
all	NULL
three	NULL
viruses	NULL
HSV-1	NULL
,	NULL
CMV	NULL
,	NULL
and	NULL
EBV	NULL
to	NULL
decrease	NULL
the	NULL
relative	NULL
amount	NULL
of	NULL
the	NULL
SUMO-1-modified	NULL
forms	NULL
of	NULL
PML	NULL
protein	NULL
.	NULL

Although	NULL
the	NULL
exact	NULL
mechanisms	NULL
by	NULL
which	NULL
herpesvirus	NULL
immediate-early	NULL
proteins	NULL
reduce	NULL
the	NULL
abundance	NULL
of	NULL
SUMO-1-modified	NULL
PML	NULL
protein	NULL
remains	NULL
unknown	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
HSV-1	NULL
,	NULL
at	NULL
least	NULL
,	NULL
this	NULL
process	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
proteosome	NULL
inhibitors	NULL
(	NULL
13	NULL
,	NULL
22	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
HSV-1	NULL
preferentially	NULL
activates	NULL
degradation	NULL
of	NULL
SUMO-modi-fied	NULL
PML	NULL
protein	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
did	NULL
not	NULL
find	NULL
that	NULL
proteosome	NULL
inhibitors	NULL
reverse	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
on	NULL
PML	NULL
protein	NULL
SUMO-1	NULL
modification	NULL
(	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

It	NULL
is	NULL
intriguing	NULL
that	NULL
both	NULL
the	NULL
Z	NULL
and	NULL
CMV	NULL
IE1	NULL
proteins	NULL
are	NULL
SUMO-1	NULL
modified	NULL
.	NULL

Thus	NULL
,	NULL
if	NULL
any	NULL
component	NULL
of	NULL
the	NULL
SUMO-1	NULL
2396	NULL
ADAMSON	NULL
AND	NULL
KENNEY	NULL
J	NULL
.	NULL

A	NULL
HA-SUMO-1	NULL
B	NULL
o	NULL
10	NULL
ug	NULL
2M	NULL
|	NULL
HA-SUMO-1	NULL
:	NULL
_-	NULL
+	NULL
-	NULL
+	NULL
]	NULL
cL	NULL
,	NULL
ian	NULL
)	NULL
10	NULL
-	NULL
Be	NULL
k	NULL
ee	NULL
ee	NULL
$	NULL
G	NULL
2	NULL
Ko	NULL
+	NULL
>	NULL
>	NULL
A	NULL
A	NULL
>	NULL
Ho	NULL
A	NULL
N	NULL
ONN	NULL
97	NULL
kD	NULL
220	NULL
kD	NULL
=x	NULL
}	NULL
pmtHia-sumo-1	NULL
-	NULL
vee	NULL
@	NULL
|	NULL
<	NULL
rmL	NULL
.	NULL

66	NULL
kD	NULL
-	NULL
_	NULL
as	NULL
22	NULL
&	NULL
P	NULL
|	NULL
7	NULL
46	NULL
kD	NULL
46	NULL
kD	NULL
-	NULL
I	NULL
20	NULL
3	NULL
4	NULL
30	NULL
kD	NULL
Io	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
66	NULL
kD	NULL
-	NULL
@	NULL
|	NULL
coral	NULL
PML	NULL
C	NULL
+	NULL
HA-	NULL
._	NULL
+	NULL
2	NULL
8	NULL
a	NULL
a	NULL
8	NULL
2	NULL
E	NULL
>	NULL
A	NULL
N	NULL
N	NULL
N	NULL
220	NULL
kD-I	NULL
@	NULL
@	NULL
sorn	NULL
watts	NULL
;	NULL
97	NULL
kD-	NULL
Â«	NULL
*	NULL
PML-SUMO-1	NULL
anti-HA	NULL
tag	NULL
551p-	NULL
.	NULL

yos	NULL
Z-SUMO-1	NULL
46	NULL
kD	NULL
-I	NULL
Â©	NULL
Io	NULL
2	NULL
0	NULL
300	NULL
40005	NULL
anti-PML	NULL
***	NULL
``	NULL
-	NULL
Â©	NULL
@	NULL
@	NULL
~~~	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Z	NULL
competes	NULL
with	NULL
PML	NULL
protein	NULL
for	NULL
SUMO-1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EBV-negative	NULL
DG75	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
vector	NULL
,	NULL
HA-SUMO-1	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
PML	NULL
protein	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
plus	NULL
HA-SUMO-1	NULL
(	NULL
2	NULL
g	NULL
)	NULL
,	NULL
Z	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
plus	NULL
HA-SUMO-1	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
,	NULL
or	NULL
Z	NULL
(	NULL
10	NULL
g	NULL
)	NULL
plus	NULL
PML	NULL
protein	NULL
(	NULL
10	NULL
mg	NULL
)	NULL
plus	NULL
HA-SUMO-1	NULL
(	NULL
2	NULL
or	NULL
10	NULL
ug	NULL
)	NULL
expression	NULL
plasmids	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-HA	NULL
antibody	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-PML	NULL
protein	NULL
monoclonal	NULL
antibody	NULL
to	NULL
check	NULL
for	NULL
total	NULL
PML	NULL
protein	NULL
levels	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-negative	NULL
DG75	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
vector	NULL
,	NULL
HA-SUMO-1	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
PML	NULL
protein	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
,	NULL
or	NULL
PML	NULL
protein	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
plus	NULL
HA-SUMO-1	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
anti-PML	NULL
protein	NULL
monoclonal	NULL
antibody	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EBV-negative	NULL
DG75	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
HA-SUMO-1	NULL
along	NULL
with	NULL
either	NULL
vector	NULL
,	NULL
PML	NULL
,	NULL
Z	NULL
,	NULL
Z	NULL
plus	NULL
PML	NULL
protein	NULL
,	NULL
or	NULL
Zm12/13	NULL
plus	NULL
PML	NULL
protein	NULL
expression	NULL
plasmids	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
each	NULL
plasmid	NULL
was	NULL
used	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-HA	NULL
antibody	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-PML	NULL
protein	NULL
monoclonal	NULL
antibody	NULL
to	NULL
check	NULL
for	NULL
total	NULL
PML	NULL
protein	NULL
levels	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

modification	NULL
machinery	NULL
is	NULL
limiting	NULL
in	NULL
cells	NULL
,	NULL
one	NULL
potential	NULL
mechanism	NULL
by	NULL
which	NULL
Z	NULL
(	NULL
and	NULL
CMV	NULL
IE1	NULL
)	NULL
could	NULL
inhibit	NULL
SUMO-1	NULL
modification	NULL
of	NULL
PML	NULL
protein	NULL
would	NULL
be	NULL
through	NULL
direct	NULL
competition	NULL
for	NULL
a	NULL
limiting	NULL
factor	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
adenovirus	NULL
E1A	NULL
protein	NULL
to	NULL
prevent	NULL
histone	NULL
acetylation	NULL
of	NULL
cellular	NULL
genes	NULL
by	NULL
direct	NULL
competition	NULL
for	NULL
CBP/p300	NULL
.	NULL

Against	NULL
this	NULL
hypothesis	NULL
is	NULL
the	NULL
finding	NULL
that	NULL
the	NULL
CMV	NULL
IE1	NULL
protein	NULL
(	NULL
which	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
Z	NULL
,	NULL
interacts	NULL
directly	NULL
with	NULL
the	NULL
PML	NULL
protein	NULL
)	NULL
inhibits	NULL
SUMO	NULL
modification	NULL
of	NULL
only	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
known	NULL
SUMO-1	NULL
substrates	NULL
(	NULL
13	NULL
,	NULL
22	NULL
,	NULL
59	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Z	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
highly	NULL
efficient	NULL
substrate	NULL
for	NULL
SUMO-1	NULL
modification	NULL
,	NULL
even	NULL
though	NULL
the	NULL
Z	NULL
,	NULL
SUMO-1	NULL
modification	NULL
site	NULL
(	NULL
DVKFT	NULL
)	NULL
does	NULL
not	NULL
conform	NULL
to	NULL
the	NULL
previously	NULL
reported	NULL
consensus	NULL
sequence	NULL
(	NULL
I/L	NULL
)	NULL
KxE	NULL
(	NULL
73	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
Z	NULL
and	NULL
SUMO-1	NULL
expression	NULL
vectors	NULL
,	NULL
Z	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
major	NULL
SUMO-1-modified	NULL
protein	NULL
in	NULL
the	NULL
host	NULL
cell	NULL
(	NULL
Figs	NULL
.	NULL

6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
and	NULL
Z	NULL
competed	NULL
with	NULL
PML	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
Zm12/13	NULL
protein	NULL
for	NULL
cotransfected	NULL
SUMO-1	NULL
.	NULL

Alternatively	NULL
,	NULL
since	NULL
phos-phorylation	NULL
of	NULL
the	NULL
PML	NULL
protein	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
SUMO-1	NULL
modification	NULL
(	NULL
60	NULL
)	NULL
,	NULL
Z	NULL
could	NULL
potentially	NULL
prevent	NULL
PML	NULL
protein	NULL
SUMO-1	NULL
modification	NULL
by	NULL
increasing	NULL
the	NULL
level	NULL
of	NULL
PML	NULL
protein	NULL
phosphorylation	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
Z	NULL
(	NULL
in	NULL
addition	NULL
to	NULL
CMV	NULL
IE1	NULL
and	NULL
IE2	NULL
)	NULL
is	NULL
only	NULL
the	NULL
third	NULL
viral	NULL
protein	NULL
shown	NULL
to	NULL
be	NULL
SUMO-1	NULL
modified	NULL
.	NULL

As	NULL
discussed	NULL
above	NULL
,	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
,	NULL
like	NULL
PML	NULL
protein	NULL
,	NULL
could	NULL
potentially	NULL
be	NULL
important	NULL
for	NULL
its	NULL
localization	NULL
to	NULL
PML	NULL
bodies	NULL
.	NULL

Alternatively	NULL
,	NULL
SUMO-1	NULL
modification	NULL
could	NULL
affect	NULL
the	NULL
stability	NULL
of	NULL
Z	NULL
or	NULL
its	NULL
interactions	NULL
with	NULL
other	NULL
proteins	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
two	NULL
SUMO-1	NULL
modification	NULL
sites	NULL
in	NULL
the	NULL
CMV	NULL
IE2	NULL
protein	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
inhibit	NULL
its	NULL
transcriptional	NULL
function	NULL
without	NULL
affecting	NULL
protein	NULL
stability	NULL
or	NULL
nuclear	NULL
localization	NULL
(	NULL
35	NULL
)	NULL
.	NULL

anti-IgG	NULL
treatment	NULL
(	NULL
--	NULL
-=	NULL
+	NULL
66	NULL
kD-	NULL
Fram	NULL
Â¢	NULL
ames	NULL
.	NULL

|	NULL
<	NULL
7_SUMO-1	NULL
46	NULL
kD-|	NULL
..	NULL
``	NULL
..	NULL
er	NULL
30	NULL
kD-	NULL
``	NULL
&	NULL
1	NULL
2	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Z	NULL
is	NULL
SUMO-1	NULL
modified	NULL
in	NULL
Akata	NULL
cells	NULL
after	NULL
induction	NULL
with	NULL
anti-IgG	NULL
cross-linking	NULL
.	NULL

Akata	NULL
cells	NULL
were	NULL
induced	NULL
to	NULL
undergo	NULL
lytic	NULL
replication	NULL
via	NULL
anti-IgG	NULL
cross-linking	NULL
for	NULL
3	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
using	NULL
conditions	NULL
which	NULL
preserve	NULL
SUMO-1	NULL
modification	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
anti-Z	NULL
polyclonal	NULL
antibody	NULL
.	NULL

The	NULL
open	NULL
arrowhead	NULL
indicates	NULL
unmodified	NULL
Z	NULL
;	NULL
the	NULL
solid	NULL
arrowhead	NULL
indicates	NULL
SUMO-1-modified	NULL
Z.	NULL
EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
_	NULL
2397	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Z	NULL
mutant	NULL
that	NULL
can	NULL
not	NULL
be	NULL
SUMO	NULL
modified	NULL
disperses	NULL
PML	NULL
bodies	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
pg	NULL
of	NULL
DNA	NULL
.	NULL

At	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
immunostained	NULL
with	NULL
anti-Z	NULL
polyclonal	NULL
antibody	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
and	NULL
anti-PML	NULL
protein	NULL
monoclonal	NULL
antibody	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Wild-type	NULL
Z	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
Zm12/13	NULL
.	NULL

Given	NULL
the	NULL
increasing	NULL
evidence	NULL
that	NULL
PML	NULL
bodies	NULL
regulate	NULL
transcription	NULL
in	NULL
the	NULL
cell	NULL
,	NULL
it	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
domain	NULL
of	NULL
Z	NULL
required	NULL
for	NULL
full	NULL
PML	NULL
body	NULL
dispersion	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
through	NULL
86	NULL
)	NULL
is	NULL
also	NULL
known	NULL
to	NULL
be	NULL
required	NULL
for	NULL
Z	NULL
transcriptional	NULL
function	NULL
(	NULL
25	NULL
)	NULL
.	NULL

An	NULL
increasing	NULL
number	NULL
of	NULL
important	NULL
cellular	NULL
transcriptional	NULL
proteins	NULL
,	NULL
including	NULL
CBP	NULL
,	NULL
p53	NULL
,	NULL
Ap-1	NULL
,	NULL
Rb	NULL
,	NULL
Daxx	NULL
,	NULL
and	NULL
Spl	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
their	NULL
interactions	NULL
with	NULL
PML	NULL
bodies	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
the	NULL
HSV-1	NULL
ICPO	NULL
protein	NULL
,	NULL
small	NULL
mutations	NULL
in	NULL
the	NULL
RING	NULL
finger	NULL
domain	NULL
which	NULL
disrupt	NULL
the	NULL
ability	NULL
of	NULL
ICPO	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
considerably	NULL
decrease	NULL
the	NULL
ability	NULL
of	NULL
ICPO	NULL
to	NULL
transcriptionally	NULL
activate	NULL
early	NULL
HSV-1	NULL
promoters	NULL
and	NULL
decrease	NULL
viral	NULL
replication	NULL
by	NULL
10-	NULL
to	NULL
100-fold	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
disperse	NULL
PML	NULL
bodies	NULL
may	NULL
likewise	NULL
be	NULL
important	NULL
for	NULL
its	NULL
transcriptional	NULL
function	NULL
and/or	NULL
its	NULL
well-described	NULL
ability	NULL
to	NULL
modulate	NULL
the	NULL
activity	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
CBP	NULL
and	NULL
p53	NULL
(	NULL
2	NULL
,	NULL
83	NULL
,	NULL
84	NULL
)	NULL
.	NULL

At	NULL
this	NULL
point	NULL
it	NULL
remains	NULL
unknown	NULL
whether	NULL
lytic	NULL
EBV	NULL
infection	NULL
,	NULL
like	NULL
HSV-1	NULL
and	NULL
CMV	NULL
infection	NULL
,	NULL
also	NULL
incorporates	NULL
PML	NULL
protein	NULL
into	NULL
replication	NULL
foci	NULL
.	NULL

The	NULL
Hayward	NULL
group	NULL
has	NULL
shown	NULL
that	NULL
a	NULL
specific	NULL
mutation	NULL
affecting	NULL
only	NULL
residues	NULL
12	NULL
and	NULL
13	NULL
in	NULL
Z	NULL
impairs	NULL
Z	NULL
replication	NULL
function	NULL
but	NULL
not	NULL
transactivator	NULL
function	NULL
(	NULL
69	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
here	NULL
,	NULL
this	NULL
mutation	NULL
also	NULL
prevents	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
.	NULL

Thus	NULL
,	NULL
SUMO-1	NULL
modification	NULL
of	NULL
Z	NULL
may	NULL
well	NULL
play	NULL
a	NULL
role	NULL
in	NULL
lytic	NULL
EBV	NULL
replication	NULL
.	NULL

Increasing	NULL
evidence	NULL
suggests	NULL
that	NULL
a	NULL
variety	NULL
of	NULL
PML	NULL
protein-dependent	NULL
functions	NULL
in	NULL
the	NULL
cell	NULL
would	NULL
be	NULL
inhibitory	NULL
to	NULL
viral	NULL
replication	NULL
in	NULL
the	NULL
host	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
PML	NULL
protein	NULL
is	NULL
required	NULL
for	NULL
apoptosis	NULL
induced	NULL
by	NULL
several	NULL
different	NULL
types	NULL
of	NULL
stim-uli	NULL
,	NULL
including	NULL
interferon	NULL
(	NULL
27	NULL
,	NULL
50	NULL
)	NULL
,	NULL
and	NULL
for	NULL
inducing	NULL
MHC	NULL
class	NULL
I	NULL
presentation	NULL
(	NULL
85	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
so	NULL
many	NULL
different	NULL
viruses	NULL
encode	NULL
mechanisms	NULL
to	NULL
disrupt	NULL
PML	NULL
body	NULL
function	NULL
suggests	NULL
that	NULL
this	NULL
protein	NULL
may	NULL
have	NULL
a	NULL
profoundly	NULL
important	NULL
role	NULL
in	NULL
vivo	NULL
for	NULL
controlling	NULL
viral	NULL
infection	NULL
.	NULL

2398	NULL
ADAMSON	NULL
AND	NULL
KENNEY	NULL
ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
2-RO1-CA58853	NULL
and	NULL
PO1-	NULL
CA19014	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

We	NULL
thank	NULL
Gary	NULL
Hayward	NULL
for	NULL
the	NULL
polyclonal	NULL
PML	NULL
antibody	NULL
,	NULL
Erik	NULL
Flemington	NULL
for	NULL
polyclonal	NULL
Z	NULL
antibody	NULL
and	NULL
various	NULL
Z	NULL
expression	NULL
plasmids	NULL
,	NULL
Ron	NULL
Evans	NULL
for	NULL
the	NULL
CMX-PML	NULL
plasmid	NULL
,	NULL
Frauke	NULL
Melchior	NULL
for	NULL
the	NULL
HA-tagged	NULL
SUMO-1	NULL
plasmid	NULL
,	NULL
Diane	NULL
Hayward	NULL
for	NULL
the	NULL
R	NULL
expression	NULL
and	NULL
Zm12/13	NULL
plasmids	NULL
,	NULL
Amy	NULL
Mauser	NULL
for	NULL
the	NULL
Z	NULL
adenovirus	NULL
vector	NULL
,	NULL
Jennifer	NULL
Swenson	NULL
for	NULL
the	NULL
R	NULL
adenovirus	NULL
vector	NULL
,	NULL
the	NULL
UNC	NULL
Gene	NULL
Therapy	NULL
Center	NULL
for	NULL
construction	NULL
of	NULL
the	NULL
adenovirus	NULL
vectors	NULL
,	NULL
and	NULL
the	NULL
UNC	NULL
Microscopy	NULL
Services	NULL
Laboratory	NULL
for	NULL
assistance	NULL
with	NULL
confocal	NULL
microscopy	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

REFERENCES	NULL
.	NULL

Adamson	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
D.	NULL
Darr	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
R.	NULL
A.	NULL
Johnson	NULL
,	NULL
A.	NULL
Mauser	NULL
,	NULL
J.	NULL
Swenson	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

2000	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
proteins	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
activate	NULL
the	NULL
ATF2	NULL
transcription	NULL
factor	NULL
by	NULL
increasing	NULL
the	NULL
levels	NULL
of	NULL
phosphorylated	NULL
p38	NULL
and	NULL
c-Jun	NULL
N-terminal	NULL
kinases	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

74:1224-1233.	NULL
.	NULL

Adamson	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
protein	NULL
interacts	NULL
physically	NULL
and	NULL
functionally	NULL
with	NULL
the	NULL
histone	NULL
acetylase	NULL
CREB-binding	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:6551-6558.	NULL
.	NULL

Ahn	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
E.	NULL
J.	NULL
Brignole	NULL
III	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Hayward	NULL
.	NULL

1998	NULL
.	NULL

Disruption	NULL
of	NULL
PML	NULL
subnuclear	NULL
domains	NULL
by	NULL
the	NULL
acidic	NULL
IE1	NULL
protein	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
is	NULL
mediated	NULL
through	NULL
interaction	NULL
with	NULL
PML	NULL
and	NULL
may	NULL
modulate	NULL
a	NULL
RING	NULL
finger-dependent	NULL
cryptic	NULL
transactivator	NULL
function	NULL
of	NULL
PML	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:4899-4913.	NULL
.	NULL

Ahn	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Hayward	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
major	NULL
immediate-early	NULL
proteins	NULL
IE1	NULL
and	NULL
IE2	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
colocalize	NULL
with	NULL
and	NULL
disrupt	NULL
PML-associated	NULL
nuclear	NULL
bodies	NULL
at	NULL
very	NULL
early	NULL
times	NULL
in	NULL
infected	NULL
permissive	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:4599-4613.	NULL
.	NULL

Ahn	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
W.	NULL
J.	NULL
Jang	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Hayward	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
human	NULL
cytomegalovirus	NULL
IE2	NULL
and	NULL
UL112-113	NULL
proteins	NULL
accumulate	NULL
in	NULL
viral	NULL
DNA	NULL
replication	NULL
compartments	NULL
that	NULL
initiate	NULL
from	NULL
the	NULL
periphery	NULL
of	NULL
promyelocytic	NULL
leukemia	NULL
protein-associated	NULL
nuclear	NULL
bodies	NULL
(	NULL
PODs	NULL
or	NULL
ND10	NULL
)	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:10458-10471.	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Tomassoni	NULL
,	NULL
E.	NULL
Colombo	NULL
,	NULL
S.	NULL
Stoldt	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
L.	NULL
Szekely	NULL
,	NULL
K.	NULL
Helin	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
product	NULL
(	NULL
PML	NULL
)	NULL
forms	NULL
stable	NULL
complexes	NULL
with	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:1084-1093.	NULL
.	NULL

Askovic	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Baumann	NULL
.	NULL

1997	NULL
.	NULL

Activation	NULL
domain	NULL
requirements	NULL
for	NULL
disruption	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
by	NULL
ZEBRA	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:6547-6554.	NULL
.	NULL

Boddy	NULL
,	NULL
M.	NULL
N.	NULL
,	NULL
K.	NULL
Howe	NULL
,	NULL
L.	NULL
D.	NULL
Etkin	NULL
,	NULL
E.	NULL
Solomon	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Freemont	NULL
.	NULL

1996	NULL
.	NULL

PIC1	NULL
,	NULL
a	NULL
novel	NULL
ubiquitin-like	NULL
protein	NULL
which	NULL
interacts	NULL
with	NULL
the	NULL
PML	NULL
component	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
that	NULL
is	NULL
disrupted	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Oncogene	NULL
13:971-982.	NULL
.	NULL

Boisvert	NULL
,	NULL
F.-M.	NULL
,	NULL
M.	NULL
J.	NULL
Hendzel	NULL
,	NULL
and	NULL
D.	NULL
P.	NULL
Bazett-Jones	NULL
.	NULL

2000	NULL
.	NULL

Promyelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
)	NULL
nuclear	NULL
bodies	NULL
are	NULL
protein	NULL
structures	NULL
that	NULL
do	NULL
not	NULL
accumulate	NULL
RNA	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

148:283-292	NULL
.	NULL

Borden	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
E.	NULL
J.	NULL
Campbell	NULL
Dwyer	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Salvato	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
promyelocytic	NULL
leukemia	NULL
protein	NULL
PML	NULL
has	NULL
a	NULL
pro-apoptotic	NULL
activity	NULL
mediated	NULL
through	NULL
its	NULL
RING	NULL
domain	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

418:30-34	NULL
.	NULL

Burkham	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
M.	NULL
Coen	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Weller	NULL
.	NULL

1998	NULL
.	NULL

ND10	NULL
protein	NULL
PML	NULL
is	NULL
recruited	NULL
to	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
prereplicative	NULL
sites	NULL
and	NULL
replication	NULL
compartments	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
viral	NULL
DNA	NULL
polymerase	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:10100-10107	NULL
.	NULL

Cayrol	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
E.	NULL
K.	NULL
Flemington	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
bZIP	NULL
transcription	NULL
factor	NULL
Zta	NULL
causes	NULL
G/G	NULL
,	NULL
cell	NULL
cycle	NULL
arrest	NULL
through	NULL
induction	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitors	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:2748-2759	NULL
.	NULL

Chelbi-Alix	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
and	NULL
H.	NULL
de	NULL
The	NULL
.	NULL

1999	NULL
.	NULL

Herpes	NULL
virus	NULL
induced	NULL
proteasome-dependent	NULL
degradation	NULL
of	NULL
the	NULL
nuclear	NULL
bodies-associated	NULL
PML	NULL
and	NULL
Sp100	NULL
proteins	NULL
.	NULL

Oncogene	NULL
18:935-941	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-encoded	NULL
trans-acting	NULL
factors	NULL
EBI	NULL
and	NULL
EB2	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
early	NULL
EBV	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1985	NULL
.	NULL

Activation	NULL
of	NULL
expression	NULL
of	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
after	NULL
gene	NULL
transfer	NULL
with	NULL
a	NULL
small	NULL
cloned	NULL
fragment	NULL
of	NULL
het-erogencous	NULL
viral	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:4085-4089	NULL
.	NULL

Cox	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivors	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:313-321	NULL
.	NULL

Desterro	NULL
,	NULL
J.	NULL
M.	NULL
P.	NULL
,	NULL
M.	NULL
S.	NULL
Rodriguez	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1998	NULL
.	NULL

SUMO-1	NULL
modification	NULL
of	NULL
IxBa	NULL
Â«	NULL
inhibits	NULL
NF-	NULL
Â«	NULL
B	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
2233-239.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Lavau	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
PML/RARa	NULL
fusion	NULL
mRNA	NULL
generated	NULL
by	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
encodes	NULL
a	NULL
functionally	NULL
altered	NULL
RAR	NULL
.	NULL

Cell	NULL
66:675-684	NULL
.	NULL

Doucas	NULL
,	NULL
V.	NULL
,	NULL
M.	NULL
Tini	NULL
,	NULL
D.	NULL
A.	NULL
Egan	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1999	NULL
.	NULL

Modulation	NULL
of	NULL
CREB	NULL
binding	NULL
protein	NULL
function	NULL
by	NULL
the	NULL
promyelocytic	NULL
(	NULL
PML	NULL
)	NULL
oncoprotein	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
nuclear	NULL
bodies	NULL
in	NULL
hormone	NULL
signaling	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96:2627-2632	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

J.	NULL
Dyck	NULL
,	NULL
J.	NULL
,	NULL
G.	NULL
G.	NULL
Maul	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
J.	NULL
D.	NULL
Chen	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
novel	NULL
macromolecular	NULL
structure	NULL
is	NULL
a	NULL
target	NULL
of	NULL
the	NULL
promyelo-cyte-retinoic	NULL
acid	NULL
receptor	NULL
oncoprotein	NULL
.	NULL

Cell	NULL
76:333-343	NULL
.	NULL

Everett	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
O'Hare	NULL
,	NULL
D.	NULL
O'Rourke	NULL
,	NULL
P.	NULL
Barlow	NULL
,	NULL
and	NULL
A.	NULL
Orr	NULL
.	NULL

1995	NULL
.	NULL

Point	NULL
mutations	NULL
in	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
Vmw110	NULL
RING	NULL
finger	NULL
helix	NULL
affect	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
,	NULL
viral	NULL
growth	NULL
,	NULL
and	NULL
interaction	NULL
with	NULL
PML-containing	NULL
nuclear	NULL
structures	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:7339-7344	NULL
.	NULL

Everett	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
P.	NULL
Freemont	NULL
,	NULL
H.	NULL
Saitoh	NULL
,	NULL
M.	NULL
Dasso	NULL
,	NULL
A.	NULL
Orr	NULL
,	NULL
M.	NULL
Kathoria	NULL
,	NULL
and	NULL
J.	NULL
Parkinson	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
disruption	NULL
of	NULL
ND10	NULL
during	NULL
herpes	NULL
simplex	NULL
virus	NULL
infection	NULL
correlates	NULL
with	NULL
the	NULL
Vmw110-	NULL
and	NULL
proteasome-dependent	NULL
loss	NULL
of	NULL
several	NULL
PML	NULL
isoforms	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:6581-6591	NULL
.	NULL

Everett	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
Maul	NULL
.	NULL

1994	NULL
.	NULL

HSV-1	NULL
IE	NULL
protein	NULL
Vmw110	NULL
causes	NULL
redistribution	NULL
of	NULL
PML	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5062-5069	NULL
.	NULL

Fagioli	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
L.	NULL
Tomassoni	NULL
,	NULL
P.	NULL
F.	NULL
Ferrucci	NULL
,	NULL
A.	NULL
Mencarelli	NULL
,	NULL
D.	NULL
Riganelli	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
T.	NULL
Pozzan	NULL
,	NULL
I.	NULL
Nicoletti	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1998	NULL
.	NULL

Cooperation	NULL
between	NULL
the	NULL
RING	NULL
+	NULL
B1-B2	NULL
and	NULL
coiled-coil	NULL
domains	NULL
of	NULL
PML	NULL
is	NULL
necessary	NULL
for	NULL
its	NULL
effects	NULL
on	NULL
cell	NULL
survival	NULL
.	NULL

Oncogene	NULL
16:2905-2913	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
M.	NULL
Borras	NULL
,	NULL
J.	NULL
P.	NULL
Lytle	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
protein	NULL
transactivation	NULL
domain	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:922-929	NULL
.	NULL

Furnari	NULL
,	NULL
F.	NULL
B.	NULL
,	NULL
V.	NULL
Zacny	NULL
,	NULL
E.	NULL
B.	NULL
Quinlivin	NULL
,	NULL
S.	NULL
Kenney	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1994	NULL
.	NULL

RAZ	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
transdominant	NULL
repressor	NULL
that	NULL
modulates	NULL
the	NULL
viral	NULL
reactivation	NULL
mechanism	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:1827-1836	NULL
.	NULL

Gaboli	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Gandini	NULL
,	NULL
L.	NULL
Delva	NULL
,	NULL
Z.	NULL
G.	NULL
Wang	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

1998	NULL
.	NULL

Acute	NULL
promyelocytic	NULL
leukemia	NULL
as	NULL
a	NULL
model	NULL
for	NULL
cross-talk	NULL
between	NULL
interferon	NULL
and	NULL
retinoic	NULL
acid	NULL
pathways	NULL
:	NULL
from	NULL
molecular	NULL
biology	NULL
to	NULL
clinical	NULL
applications	NULL
.	NULL

Leuk	NULL
.	NULL

Lymphoma	NULL
30:11-22	NULL
.	NULL

Giot	NULL
,	NULL
J.-F.	NULL
,	NULL
I.	NULL
Mikaelian	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
I.	NULL
Joab	NULL
,	NULL
J.-C.	NULL
Nicolas	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
synergy	NULL
and	NULL
interference	NULL
between	NULL
the	NULL
EBV	NULL
transcription	NULL
factors	NULL
EB1	NULL
and	NULL
R	NULL
require	NULL
both	NULL
the	NULL
basic	NULL
region	NULL
and	NULL
the	NULL
activation	NULL
domains	NULL
of	NULL
EB1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1251-1258	NULL
.	NULL

Glaser	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
F.	NULL
J.	NULL
O'Neill	NULL
.	NULL

1972	NULL
.	NULL

Hybridization	NULL
of	NULL
Burkitt	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Science	NULL
176:1245-1247	NULL
.	NULL

Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
P.	NULL
S.	NULL
Borrow	NULL
,	NULL
P.	NULL
S.	NULL
Freemont	NULL
,	NULL
and	NULL
E.	NULL
Solomon	NULL
.	NULL

1991	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
zinc	NULL
finger	NULL
gene	NULL
disrupted	NULL
by	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Science	NULL
254:1371-1374	NULL
.	NULL

Gongora	NULL
,	NULL
C.	NULL
,	NULL
G.	NULL
David	NULL
,	NULL
L.	NULL
Pintard	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
a	NULL
new	NULL
interferon-induced	NULL
PML	NULL
nuclear	NULL
body-associated	NULL
protein	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:19457-19463	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
,	NULL
R	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
cytoplasmic	NULL
early	NULL
anti-gen.	NULL
J.	NULL
Virol	NULL
.	NULL

62:2274-2284	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
L.	NULL
Tse	NULL
,	NULL
N.	NULL
Applegren	NULL
,	NULL
J.	NULL
Nicholas	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Veliuona	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
R	NULL
transactivator	NULL
(	NULL
Rta	NULL
)	NULL
contains	NULL
a	NULL
complex	NULL
,	NULL
potent	NULL
activation	NULL
domain	NULL
with	NULL
properties	NULL
different	NULL
from	NULL
those	NULL
of	NULL
VP16	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5500-5508	NULL
.	NULL

He	NULL
,	NULL
L.	NULL
Z.	NULL
,	NULL
T.	NULL
Merghoub	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

1999	NULL
.	NULL

In	NULL
vivo	NULL
analysis	NULL
of	NULL
the	NULL
molecular	NULL
pathogenesis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
in	NULL
the	NULL
mouse	NULL
and	NULL
its	NULL
therapeutic	NULL
implications	NULL
.	NULL

Oncogene	NULL
18:5278-5292	NULL
.	NULL

Hofmann	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
Floss	NULL
,	NULL
and	NULL
T.	NULL
Stamminger	NULL
.	NULL

2000	NULL
.	NULL

Covalent	NULL
modification	NULL
of	NULL
the	NULL
transactivator	NULL
protein	NULL
IE2-p86	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
by	NULL
conjugation	NULL
to	NULL
the	NULL
ubiquitin-homologous	NULL
proteins	NULL
SUMO-1	NULL
and	NULL
hSMT3b	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

74	NULL
:	NULL
2510-2524	NULL
.	NULL

Holley-Guthrie	NULL
,	NULL
E.	NULL
,	NULL
E.	NULL
Quinlivin	NULL
,	NULL
E.	NULL
Mar	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
promoter	NULL
for	NULL
early	NULL
antigen	NULL
(	NULL
EA-D	NULL
)	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
EBV	NULL
transactivators	NULL
BRLF1	NULL
and	NULL
BZLFI1	NULL
in	NULL
a	NULL
cell-specific	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3753-3759	NULL
.	NULL

Ishov	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
A.	NULL
G.	NULL
Sotnikov	NULL
,	NULL
D.	NULL
Negorev	NULL
,	NULL
O.	NULL
V.	NULL
Viadimirova	NULL
,	NULL
N.	NULL
Neff	NULL
,	NULL
T.	NULL
Kamitani	NULL
,	NULL
E.	NULL
T.	NULL
Yeh	NULL
,	NULL
J.	NULL
F.	NULL
Strauss	NULL
III	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
Maul	NULL
.	NULL

1999	NULL
.	NULL

PML	NULL
is	NULL
critical	NULL
for	NULL
ND10	NULL
formation	NULL
and	NULL
recruits	NULL
the	NULL
PML-interacting	NULL
protein	NULL
daxx	NULL
to	NULL
this	NULL
nuclear	NULL
structure	NULL
when	NULL
modified	NULL
by	NULL
SUMO-1	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

147:221-234	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
R.	NULL
P.	NULL
Warrell	NULL
,	NULL
S.	NULL
R.	NULL
Frankel	NULL
,	NULL
V.	NULL
V.	NULL
V.	NULL
S.	NULL
Murty	NULL
,	NULL
E.	NULL
Dmitrovsky	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
RARa	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cell	NULL
66:663-674	NULL
.	NULL

Kamitani	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
P.	NULL
Nguyen	NULL
,	NULL
and	NULL
E.	NULL
T.	NULL
H.	NULL
Yeh	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
NEDD8	NULL
,	NULL
a	NULL
developmentally	NULL
down-regulated	NULL
ubiquitin-like	NULL
protein	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:14001-14004	NULL
.	NULL

Kelly	NULL
,	NULL
C.	NULL
,	NULL
R.	NULL
van	NULL
Driel	NULL
,	NULL
and	NULL
G.	NULL
W.	NULL
Wilkinson	NULL
.	NULL

1995	NULL
.	NULL

Disruption	NULL
of	NULL
PML-associated	NULL
bodies	NULL
during	NULL
human	NULL
cytomegalovirus	NULL
infection	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

76:2887-2893	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
M.	NULL
Smith	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BMLF1	NULL
promoter	NULL
contains	NULL
an	NULL
enhancer	NULL
element	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
the	NULL
BZLF1	NULL
and	NULL
BRLFI1	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3878-3883	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.	NULL
Quinlivan	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
T.	NULL
Bender	NULL
,	NULL
J.	NULL
Giot	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
cellular	NULL
oncogene	NULL
c-myb	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
transactivator	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:136-146	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
J.-C.	NULL
Lin	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
J.	NULL
Pagano	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
BZLF1	NULL
immediate-early	NULL
gene	NULL
product	NULL
differentially	NULL
affects	NULL
latent	NULL
versus	NULL
productive	NULL
EBV	NULL
promoters	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1729-1736	NULL
.	NULL

Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
,	NULL
p.	NULL
2343-2396	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Lippincott-Raven	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Koken	NULL
,	NULL
M.	NULL
H.	NULL
M.	NULL
1994	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
alters	NULL
a	NULL
nuclear	NULL
body	NULL
in	NULL
a	NULL
retinoic	NULL
acid-reversible	NULL
fashion	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:1073-1083	NULL
.	NULL

Korioth	NULL
,	NULL
F.	NULL
,	NULL
G.	NULL
G.	NULL
Maul	NULL
,	NULL
B.	NULL
Plachter	NULL
,	NULL
T.	NULL
Stamminger	NULL
and	NULL
J.	NULL
Frey	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
nuclear	NULL
domain	NULL
10	NULL
(	NULL
ND10	NULL
)	NULL
is	NULL
disrupted	NULL
by	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
gene	NULL
product	NULL
IE1	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

229:155-158	NULL
.	NULL

Kouzarides	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Packham	NULL
,	NULL
A.	NULL
Cook	NULL
,	NULL
and	NULL
P.	NULL
Farrell	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
BZLF1	NULL
protein	NULL
of	NULL
EBV	NULL
has	NULL
a	NULL
coiled-coil	NULL
dimerization	NULL
domain	NULL
without	NULL
a	NULL
heptad	NULL
leucine	NULL
repeat	NULL
but	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
C/EBP	NULL
leucine	NULL
zipper	NULL
.	NULL

Oncogene	NULL
6:195-204	NULL
.	NULL

LaMorte	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
R.	NULL
L.	NULL
Ochs	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1998	NULL
.	NULL

Localization	NULL
of	NULL
nascent	NULL
RNA	NULL
and	NULL
CREB	NULL
binding	NULL
protein	NULL
with	NULL
the	NULL
PML-containing	NULL
nuclear	NULL
body	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:4991-4996	NULL
.	NULL

Lapenta	NULL
,	NULL
V.	NULL
,	NULL
P.	NULL
Chiurazzi	NULL
,	NULL
P.	NULL
van	NULL
der	NULL
Spek	NULL
,	NULL
A.	NULL
Pizzuti	NULL
,	NULL
F.	NULL
Hanaoka	NULL
,	NULL
and	NULL
C.	NULL
Brahe	NULL
.	NULL

1997	NULL
.	NULL

SMT3A	NULL
,	NULL
a	NULL
human	NULL
homologue	NULL
of	NULL
the	NULL
S.	NULL
cerevisiae	NULL
SMT3	NULL
gene	NULL
,	NULL
maps	NULL
to	NULL
chromosome	NULL
21qter	NULL
and	NULL
defines	NULL
a	NULL
novel	NULL
gene	NULL
family	NULL
.	NULL

Genomics	NULL
40:362-366	NULL
.	NULL

Lavau	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
J.	NULL
Jansen	NULL
,	NULL
B.	NULL
Falini	NULL
,	NULL
P.	NULL
Lebon	NULL
,	NULL
F.	NULL
Gros-veld	NULL
,	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
acute	NULL
promyelocytic	NULL
leukemia-associated	NULL
PML	NULL
gene	NULL
is	NULL
induced	NULL
by	NULL
interferon	NULL
.	NULL

Oncogene	NULL
11:871-876	NULL
.	NULL

Li	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Leo	NULL
,	NULL
J.	NULL
Zhu	NULL
,	NULL
X.	NULL
Wu	NULL
,	NULL
J.	NULL
O'Neil	NULL
,	NULL
E.	NULL
J	NULL
.	NULL

Park	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Chen	NULL
.	NULL

2000	NULL
.	NULL

Sequestration	NULL
and	NULL
inhibition	NULL
of	NULL
daxx-mediated	NULL
transcriptional	NULL
repression	NULL
by	NULL
PML	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

20:1784-1796	NULL
.	NULL

Li	NULL
,	NULL
Q.	NULL
X.	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
G.	NULL
Niedobitek	NULL
,	NULL
C.	NULL
W.	NULL
Dawson	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
infection	NULL
and	NULL
replication	NULL
in	NULL
a	NULL
human	NULL
epithelial	NULL
cell	NULL
system	NULL
.	NULL

Nature	NULL
356:347-350	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1989	NULL
.	NULL

Responsiveness	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
NofI	NULL
repeat	NULL
promoter	NULL
to	NULL
the	NULL
Z	NULL
transactivator	NULL
is	NULL
mediated	NULL
in	NULL
a	NULL
cell	NULL
type-specific	NULL
manner	NULL
by	NULL
two	NULL
independent	NULL
signal	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3040-3050	NULL
.	NULL

Mahajan	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Delphin	NULL
,	NULL
T.	NULL
Guan	NULL
,	NULL
L.	NULL
Gerace	NULL
,	NULL
and	NULL
F.	NULL
Melchior	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
small	NULL
ubiquitin-related	NULL
polypeptide	NULL
involved	NULL
in	NULL
targeting	NULL
RanGAP1	NULL
to	NULL
nuclear	NULL
pore	NULL
complex	NULL
protein	NULL
RanBP2	NULL
.	NULL

Cell	NULL
88:97-107	NULL
.	NULL

Mahajan	NULL
,	NULL
R.	NULL
,	NULL
L.	NULL
Gerace	NULL
,	NULL
and	NULL
F.	NULL
Melchior	NULL
.	NULL

1998	NULL
.	NULL

Molecular	NULL
characterization	NULL
of	NULL
the	NULL
SUMO-1	NULL
modification	NULL
of	NULL
RanGAP1	NULL
and	NULL
its	NULL
role	NULL
in	NULL
nuclear	NULL
envelope	NULL
association	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

140:259-270	NULL
.	NULL

Matunis	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
E.	NULL
Coutavas	NULL
,	NULL
and	NULL
G.	NULL
Blobel	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
novel	NULL
ubiquitin-like	NULL
modification	NULL
modulates	NULL
the	NULL
partitioning	NULL
of	NULL
the	NULL
Ran-GTPase-activating	NULL
protein	NULL
RanGAP1	NULL
between	NULL
the	NULL
cytosol	NULL
and	NULL
the	NULL
nuclear	NULL
pore	NULL
complex	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

135:1457-1470	NULL
.	NULL

Maul	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Everett	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
nuclear	NULL
location	NULL
of	NULL
PML	NULL
,	NULL
a	NULL
cellular	NULL
member	NULL
of	NULL
the	NULL
C3HC4	NULL
zinc	NULL
binding	NULL
domain	NULL
protein	NULL
family	NULL
,	NULL
is	NULL
rearranged	NULL
during	NULL
herpes	NULL
virus	NULL
infection	NULL
by	NULL
the	NULL
C3HC4	NULL
viral	NULL
protein	NULL
ICPO	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

75:1223-1233	NULL
.	NULL

Melnick	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Licht	NULL
.	NULL

1999	NULL
.	NULL

Deconstructing	NULL
a	NULL
disease	NULL
:	NULL
RARa	NULL
,	NULL
its	NULL
fusion	NULL
partners	NULL
,	NULL
and	NULL
their	NULL
roles	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
93:3167-3215	NULL
.	NULL

Muller	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1999	NULL
.	NULL

Viral	NULL
immediate-early	NULL
proteins	NULL
abrogate	NULL
the	NULL
modification	NULL
by	NULL
SUMO-1	NULL
of	NULL
PML	NULL
and	NULL
$	NULL
p100	NULL
proteins	NULL
,	NULL
correlating	NULL
with	NULL
nuclear	NULL
body	NULL
disruption	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:5137-5143	NULL
.	NULL

Muller	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
J.	NULL
Matunis	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1998	NULL
.	NULL

Conjugation	NULL
with	NULL
the	NULL
ubiquitin-related	NULL
modifier	NULL
SUMO-1	NULL
regulates	NULL
the	NULL
partitioning	NULL
of	NULL
PML	NULL
within	NULL
the	NULL
nucleus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:61-70	NULL
.	NULL

Packham	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Economou	NULL
,	NULL
C.	NULL
M.	NULL
Rooney	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1990	NULL
.	NULL

Structure	NULL
and	NULL
function	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2110-2116	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
A.	NULL
Mencarelli	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
G.	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1991	NULL
.	NULL

Structure	NULL
and	NULL
origin	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RARa	NULL
Â«	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retin-oid-binding	NULL
ability	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
6:1285-1292	NULL
.	NULL

Quignon	NULL
,	NULL
F.	NULL
,	NULL
F.	NULL
De	NULL
Bels	NULL
,	NULL
M.	NULL
Koken	NULL
,	NULL
J.	NULL
Feunteun	NULL
,	NULL
J.	NULL
C.	NULL
Ameisin	NULL
,	NULL
and	NULL
H.	NULL
de	NULL
The	NULL
.	NULL

1998	NULL
.	NULL

PML	NULL
induces	NULL
a	NULL
novel	NULL
caspase-independent	NULL
death	NULL
process	NULL
.	NULL

Nature	NULL
Genet	NULL
.	NULL

20:259-265	NULL
.	NULL

Quinlivan	NULL
,	NULL
E.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
M.	NULL
Norris	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
S.	NULL
Bachenheimer	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1993	NULL
.	NULL

Direct	NULL
BRLF1	NULL
binding	NULL
is	NULL
required	NULL
for	NULL
cooperative	NULL
BZLFI/BRLF1	NULL
activation	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
promoter	NULL
BMRFI1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21:1999-2007	NULL
.	NULL

Ragoczy	NULL
,	NULL
T.	NULL
,	NULL
L.	NULL
Heston	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
Rta	NULL
protein	NULL
activates	NULL
lytic	NULL
cycle	NULL
genes	NULL
and	NULL
can	NULL
disrupt	NULL
latency	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:7978-7984	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
,	NULL
p.	NULL
2397-2446	NULL
.	NULL

In	NULL
67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
71.	NULL
i	NULL
72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

B	NULL
75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

81	NULL
.	NULL

82	NULL
.	NULL

83	NULL
.	NULL

84	NULL
.	NULL

85	NULL
.	NULL

86	NULL
.	NULL

87	NULL
.	NULL

~	NULL
88	NULL
.	NULL

EBV	NULL
DISPERSES	NULL
PML	NULL
BODIES	NULL
_	NULL
2399	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Lippincott-Raven	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Rooney	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Rowe	NULL
,	NULL
T.	NULL
Ragot	NULL
,	NULL
and	NULL
P.	NULL
Farrell	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
spliced	NULL
BZLF1	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
transactivates	NULL
an	NULL
early	NULL
EBV	NULL
promoter	NULL
and	NULL
induces	NULL
the	NULL
virus	NULL
productive	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3109-3116	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
,	NULL
N.	NULL
Taylor	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
J.	NULL
Kolman	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1988	NULL
.	NULL

Genome	NULL
rearrangements	NULL
activate	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
whose	NULL
product	NULL
disrupts	NULL
latency	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9801-9805	NULL
.	NULL

Sarisky	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Z.	NULL
Gao	NULL
,	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
E.	NULL
D.	NULL
Fixman	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
replication	NULL
function	NULL
associated	NULL
with	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
transactivator	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:8340-8347	NULL
.	NULL

Shen	NULL
,	NULL
Z.	NULL
,	NULL
P.	NULL
E.	NULL
Pardington-Purtymun	NULL
,	NULL
J.	NULL
C.	NULL
Comeaux	NULL
,	NULL
R.	NULL
K.	NULL
Moyzis	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Chen	NULL
.	NULL

1996	NULL
.	NULL

Associations	NULL
of	NULL
UBE2ZI	NULL
with	NULL
RADS2	NULL
,	NULL
UBL1	NULL
,	NULL
p53	NULL
,	NULL
and	NULL
RADS1	NULL
proteins	NULL
in	NULL
a	NULL
yeast	NULL
two-hybrid	NULL
system	NULL
.	NULL

Genomics	NULL
37:183-186	NULL
.	NULL

Sixby	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
J.	NULL
G.	NULL
Nedrud	NULL
,	NULL
N.	NULL
Raab-Traub	NULL
,	NULL
R.	NULL
A.	NULL
Hanes	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1984	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
replication	NULL
in	NULL
oropharyngeal	NULL
epithelial	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

310:1225-1230	NULL
.	NULL

Sternsdorf	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Jensen	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1997	NULL
.	NULL

Evidence	NULL
for	NULL
covalent	NULL
modification	NULL
of	NULL
the	NULL
nuclear	NULL
dot-associated	NULL
proteins	NULL
PML	NULL
and	NULL
Sp100	NULL
by	NULL
PIC1/	NULL
SUMO-1	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

139:1621-1634	NULL
.	NULL

Sternsdorf	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Jensen	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
nuclear	NULL
dot	NULL
protein	NULL
sp100	NULL
:	NULL
characterization	NULL
of	NULL
domains	NULL
necessary	NULL
for	NULL
dimerization	NULL
,	NULL
subcellular	NULL
localization	NULL
,	NULL
and	NULL
modification	NULL
by	NULL
small	NULL
ubiquitin-like	NULL
modifers	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
:	NULL
12555-12566	NULL
.	NULL

Szostecki	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
H.	NULL
Guldner	NULL
,	NULL
H.	NULL
J.	NULL
Netter	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1990	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
cDNA	NULL
encoding	NULL
a	NULL
human	NULL
nuclear	NULL
antigen	NULL
predominantly	NULL
recognized	NULL
by	NULL
autoantibodies	NULL
from	NULL
patients	NULL
with	NULL
primary	NULL
biliary	NULL
cirrhosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:4338-4347	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Shimizu	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1986	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:1016-1022	NULL
.	NULL

Tonneguzzo	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
C.	NULL
Hayday	NULL
,	NULL
and	NULL
A.	NULL
Keating	NULL
.	NULL

1986	NULL
.	NULL

Electric	NULL
field-mediated	NULL
DNA	NULL
transfer	NULL
:	NULL
transient	NULL
and	NULL
stable	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:703-706	NULL
.	NULL

Torii	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
A.	NULL
Egan	NULL
,	NULL
R.	NULL
A.	NULL
Evans	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1999	NULL
.	NULL

Human	NULL
Daxx	NULL
regulates	NULL
Fas-induced	NULL
apoptosis	NULL
from	NULL
nuclear	NULL
PNL	NULL
oncogenic	NULL
domains	NULL
(	NULL
PODs	NULL
)	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

18:6037-6049	NULL
.	NULL

Urier	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
protein	NULL
EB1	NULL
activates	NULL
transcription	NULL
from	NULL
different	NULL
responsive	NULL
elements	NULL
including	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1447-1453	NULL
.	NULL

Wang	NULL
,	NULL
Z.-G.	NULL
,	NULL
D.	NULL
Ruggero	NULL
,	NULL
S.	NULL
Ronchetti	NULL
,	NULL
S.	NULL
Zhong	NULL
,	NULL
M.	NULL
Gaboli	NULL
,	NULL
R.	NULL
Rivi	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

1998	NULL
.	NULL

PML	NULL
is	NULL
essential	NULL
for	NULL
multiple	NULL
apoptotic	NULL
pathways	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

20:266-271	NULL
.	NULL

Weis	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Rambaud	NULL
,	NULL
C.	NULL
Lavau	NULL
,	NULL
J.	NULL
Jansen	NULL
,	NULL
T.	NULL
Carvalho	NULL
,	NULL
M.	NULL
Carmo-Fonseca	NULL
,	NULL
A.	NULL
Lamond	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1994	NULL
.	NULL

Retinoic	NULL
acid	NULL
regulates	NULL
aberrant	NULL
nuclear	NULL
localization	NULL
of	NULL
PML-RARa	NULL
Â«	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemic	NULL
cells	NULL
.	NULL

Cell	NULL
76	NULL
:	NULL
345-356	NULL
.	NULL

Westphal	NULL
,	NULL
E.-M.	NULL
,	NULL
A.	NULL
Mauser	NULL
,	NULL
J.	NULL
Swenson	NULL
,	NULL
M.	NULL
G.	NULL
Davis	NULL
,	NULL
C.	NULL
L.	NULL
Talarico	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Kenney	NULL
.	NULL

1999	NULL
.	NULL

Induction	NULL
of	NULL
lytic	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infection	NULL
in	NULL
EBV-associated	NULL
malignancies	NULL
using	NULL
adenovirus	NULL
vectors	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

59:1485-1491	NULL
.	NULL

Zalani	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
viral	NULL
latency	NULL
is	NULL
disrupted	NULL
by	NULL
the	NULL
immediate-early	NULL
BRLF1	NULL
protein	NULL
through	NULL
a	NULL
cell-specific	NULL
mechanism	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:9194-9199	NULL
.	NULL

Zerby	NULL
,	NULL
D.	NULL
,	NULL
C.-J	NULL
.	NULL

Chen	NULL
,	NULL
E.	NULL
Poon	NULL
,	NULL
D.	NULL
Lee	NULL
,	NULL
R.	NULL
Shichattar	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Lieberman	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
amino-terminal	NULL
C/H1	NULL
domain	NULL
of	NULL
CREB-binding	NULL
protein	NULL
mediates	NULL
Zta	NULL
transcriptional	NULL
activation	NULL
of	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19:1617-1626	NULL
.	NULL

Zhang	NULL
,	NULL
Q.	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
and	NULL
physical	NULL
interaction	NULL
between	NULL
p53	NULL
and	NULL
BZLF1	NULL
:	NULL
implications	NULL
for	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1929-1938	NULL
.	NULL

Zheng	NULL
,	NULL
P.	NULL
,	NULL
Y.	NULL
Guo	NULL
,	NULL
Q.	NULL
Niu	NULL
,	NULL
D.	NULL
E.	NULL
Levy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
S.	NULL
Lu	NULL
,	NULL
L.	NULL
A.	NULL
Sheiman	NULL
,	NULL
and	NULL
Y.	NULL
Liu	NULL
.	NULL

1998	NULL
.	NULL

Proto-oncogene	NULL
PML	NULL
controls	NULL
genes	NULL
devoted	NULL
to	NULL
MHC	NULL
class	NULL
I	NULL
antigen	NULL
presentation	NULL
.	NULL

Nature	NULL
396:373-376	NULL
.	NULL

Zhong	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Muller	NULL
,	NULL
S.	NULL
Ronchetti	NULL
,	NULL
P.	NULL
S.	NULL
Freemont	NULL
,	NULL
A.	NULL
Dejean	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

2000	NULL
.	NULL

Role	NULL
of	NULL
SUMO-1-modified	NULL
PML	NULL
in	NULL
nuclear	NULL
body	NULL
formation	NULL
.	NULL

Blood	NULL
95:2748-2753	NULL
.	NULL

Zhong	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Salomoni	NULL
,	NULL
S.	NULL
Ronchetti	NULL
,	NULL
A.	NULL
Guo	NULL
,	NULL
D.	NULL
Ruggero	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

2000	NULL
.	NULL

PML	NULL
and	NULL
Daxx	NULL
participate	NULL
in	NULL
a	NULL
novel	NULL
nuclear	NULL
pathway	NULL
for	NULL
apoptosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

191:631-640.	NULL
zur	NULL
Hausen	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Schulte-Holthauzen	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
G.	NULL
Henle	NULL
,	NULL
W.	NULL
Henle	NULL
,	NULL
P.	NULL
Clifford	NULL
,	NULL
and	NULL
L.	NULL
Santesson	NULL
.	NULL

1970	NULL
.	NULL

EBV	NULL
DNA	NULL
in	NULL
biopsies	NULL
of	NULL
Burkitt	NULL
tumours	NULL
and	NULL
anaplastic	NULL
carcinomas	NULL
of	NULL
the	NULL
nasopharynx	NULL
.	NULL

Nature	NULL
228:1956-1958	NULL
.	NULL

